var title_f29_36_30272="Pediatric femoral neck stress fracture";
var content_f29_36_30272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Femoral neck stress fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compression side stress fracture of the femoral neck in a seven year old \"select\" soccer player. This healed uneventfully after restriction of activity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Klane White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30272=[""].join("\n");
var outline_f29_36_30272=null;
var title_f29_36_30273="Gottrons sign in DM I";
var content_f29_36_30273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gottron's sign in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous, scaly eruption over the extensor surfaces of the metacarpophalangeal joints and digits in a patient with dermatomyositis. These lesions, called Gottron's sign, can mimic psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30273=[""].join("\n");
var outline_f29_36_30273=null;
var title_f29_36_30274="St Marks deep pelvic retractor";
var content_f29_36_30274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    St. Mark's deep pelvic retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    St. Mark's deep pelvic retractor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image provided by Dr. Michael Edwards. Available at: file://www.wikisurgery.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30274=[""].join("\n");
var outline_f29_36_30274=null;
var title_f29_36_30275="Clevidipine: Patient drug information";
var content_f29_36_30275=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clevidipine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/25/39317?source=see_link\">",
"     see \"Clevidipine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6269610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cleviprex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701822",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clevidipine, eggs, soy products, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart valve problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12134 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30275=[""].join("\n");
var outline_f29_36_30275=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6269610\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013603\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013602\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013606\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013607\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013609\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013605\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013610\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013611\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/25/39317?source=related_link\">",
"      Clevidipine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_36_30276="Coronavirus structure";
var content_f29_36_30276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Model of coronavirus structure: A schematic diagram of virion structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Field's Virology, 5th edition, Knipe DM, Howley PM, Griffin DE (Eds), Lippincott Williams &amp; Wilkins, Philadelphia,&nbsp;2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30276=[""].join("\n");
var outline_f29_36_30276=null;
var title_f29_36_30277="Autoimmune chronic hepatitis enlarged portal triad";
var content_f29_36_30277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Autoimmune chronic hepatitis, enlarged portal triad (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One portal triad is greatly enlarged, infiltrated with primarily mononuclear inflammatory cells, and demonstrates striking interface hepatitis. The other portal triads are enlarged, but not nearly to the same degree.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30277=[""].join("\n");
var outline_f29_36_30277=null;
var title_f29_36_30278="Anterior temporal lobe CADASIL";
var content_f29_36_30278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Anterior temporal lobe involvement in CADASIL",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Brain MRI of a 46 year old male with CADASIL and skin biopsy positive for granular osmiophilic material. There is hyperintensity in the periventricular and subcortical white matter on T2-weighted (A) and FLAIR (B) sequences, a nonspecific pattern that may be seen with other small vessel ischemic disease processes. In addition, there is increased signal intensity in the anterior temporal lobe white matter on T2-weighted (D) and FLAIR (E) sequences, a finding that may be more specific for CADASIL. Additional findings include a right periventricular lacunar infarction of CSF signal intensity (A, B, C) and involvement of the pons (D, E).",
"    <div class=\"footnotes\">",
"     Images courtesy of Eric Schwartz, MD",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30278=[""].join("\n");
var outline_f29_36_30278=null;
var title_f29_36_30279="Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis";
var content_f29_36_30279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30279/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30279/contributors\">",
"     Jack JH Bleesing, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30279/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30279/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30279/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30279/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/36/30279/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1698604\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune lymphoproliferative syndrome (ALPS) is characterized by dysregulation of the immune system, due to an inability to regulate lymphocyte homeostasis through the process of lymphocyte apoptosis (a form of programmed cell death). The consequences of this include lymphoproliferative disease, manifested by lymphadenopathy, hepatomegaly, splenomegaly, and an increased risk of lymphoma, as well as autoimmune disease, typically involving blood cells.",
"   </p>",
"   <p>",
"    The signature laboratory abnormalities that facilitate diagnosis of ALPS include an expansion of T cells that express the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptor but lack both CD4 and CD8",
"    <span class=\"nowrap\">",
"     (alpha/beta",
"    </span>",
"    double-negative T cells, or DNT cells) in peripheral blood and tissue specimens, elevated levels of interleukin (IL)-10 in blood, increased levels of vitamin B12, and defective Fas-mediated apoptosis",
"    <em>",
"     in vitro",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1698840\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALPS-FAS is the most common and best-characterized type of ALPS. The following are the main consequences of perturbed lymphocyte homeostasis in ALPS-FAS:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1698847\">",
"    <span class=\"h2\">",
"     Chronic nonmalignant lymphoproliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expansion of lymphocyte populations that are not eliminated through apoptosis affects the lymphoid compartment, resulting in lymphadenopathy, splenomegaly with or without premature destruction of blood cells (hypersplenism), and, less frequently, hepatomegaly. The lymphoproliferation typically manifests in the first years of life in individuals with ALPS-FAS. In some individuals, splenomegaly is the predominant or only manifestation of lymphoproliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphadenopathy tends to decrease in the second decade, whereas splenomegaly often does not. Furthermore, long-term follow-up has shown that resolution of lymphadenopathy is not always accompanied by significant changes in the overall expansion of lymphocyte subsets in peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/3\">",
"     3",
"    </a>",
"    ]. The lymphoproliferation waxes and wanes for reasons that are not entirely clear. Intercurrent viral and bacterial infections can influence lymphadenopathy, but both increased and decreased intensity of lymphoproliferative manifestations have been observed with infections, making it difficult to predict the effect of infection or to understand the mechanism responsible. The overall prognosis of lymphoproliferation is relatively good and few individuals require long-term treatment with immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1698854\">",
"    <span class=\"h2\">",
"     Autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmunity is a common feature of ALPS, although it is not always present at the time of diagnosis or at the time of the most extensive lymphoproliferation. The reason for this delay in onset is unclear, but may be related to age-dependent acquisition of secondary pathogenic factors or sequential exposures to infectious agents during infancy and early childhood. In some cases, autoimmunity is the first ALPS manifestation. In many individuals, autoantibodies can be detected some time before the appearance of clinical evidence of autoimmune disease, and it is possible that certain patients never develop autoimmunity despite the presence of autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmunity most often involves combinations of Coombs-positive autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Autoimmune neutropenia (AIN) is less common. Combinations of the above, either concomitantly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sequentially typically occur, with AIHA and ITP as the most common combination, followed by ITP and AIN. Combination cytopenias are also referred to as Evans syndrome. The presence of Evans syndrome without significant lymphoproliferation can be consistent with ALPS, especially if DNT cells are present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link\">",
"     \"Autoimmune hemolytic anemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link&amp;anchor=H4#H4\">",
"     \"Immune neutropenia\", section on 'Autoimmune neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autoimmune cytopenias may be difficult to distinguish from the effects of concomitant hypersplenism. Examination of blood smears for evidence of hemolysis, measurement of autoantibodies, and the degree of reticulocytosis may help in distinguishing one from the other, as well as the fact that autoimmune cytopenias often manifest clinically (eg, bleeding). This also helps in distinguishing ALPS-related immune thrombocytopenia from idiopathic immune thrombocytopenia, which can be experienced without significant bleeding issues.",
"   </p>",
"   <p>",
"    Additional autoimmune features are seen, often in patterns that appear to be family-specific, suggesting the influence of other (background) genes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. These features include glomerulonephritis, autoimmune hepatitis, Guillain Barr&eacute; syndrome, uveitis, and iridocyclitis. Autoimmunity affecting endocrine systems is not common in ALPS, compared with other immunodeficiency disorders.",
"   </p>",
"   <p>",
"    Autoimmune manifestations also wax and wane, although experience suggests that autoimmune disease poses a lifelong risk and burden. In many patients, the occurrence of autoimmunity signifies the transition from ALPS without the need for immunosuppressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunomodulating therapy into ALPS requiring long-term",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intermittent therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1698861\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with ALPS-FAS are at an increased risk for both Hodgkin and non-Hodgkin lymphoma, underscoring the role of",
"    <em>",
"     FAS",
"    </em>",
"    as a tumor-suppressor gene. In one study, the calculated increased risk was 14-fold and 51-fold for non-Hodgkin and Hodgkin lymphoma, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/8\">",
"     8",
"    </a>",
"    ]. Lymphoma typically originates in B cells, but can arise in T cells as well. Lymphoma is not related to EBV infection, based upon absence of EBV in tumor biopsies.",
"   </p>",
"   <p>",
"    Clinical experience suggests that lymphomas can occur at any age in ALPS-FAS. Distinguishing a \"good\" node from a \"bad\" node is a diagnostic challenge, because of the frequent concomitant presence of benign (ie, \"typical\") lymphadenopathy and splenomegaly. Important clues are B-type symptoms including fever, night sweats, itching, and weight loss. In addition, positron omission tomography (PET)-based imaging may be helpful distinguishing &ldquo;good&rdquo; from &ldquo;bad&rdquo; nodes on the basis of presumed higher metabolic activity of malignant lymphoid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/9\">",
"     9",
"    </a>",
"    ]. Nonmalignant lymphadenopathy varies over time and experience suggests that PET scan results fluctuate similarly with respect to the localization of &ldquo;hot&rdquo; (chemically active) versus &ldquo;cold&rdquo; nodes. In contrast, lymphoma nodes are more likely to be persistently hot. Further data are needed to prove PET scans are a useful routine surveillance tool.",
"   </p>",
"   <p>",
"    A number of studies have looked at associations between Fas and neoplasms, including somatic mutations in solid tumors, leukemias, and lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. To date there is no evidence for an increased risk for malignancies other than lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1698868\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients report skin rashes, such as urticaria and eczema, as well as less frequent manifestations, such as vasculitis, panniculitis,",
"    <span class=\"nowrap\">",
"     arthritis/arthralgia,",
"    </span>",
"    and recurrent oral ulcers. Constitutional signs, including fever, night sweats, and weight loss, are uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1698875\">",
"    <span class=\"h2\">",
"     Other ALPS genotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much less can be said with certainty with respect to the other ALPS genotypes, as there are only a few cases. The several patients identified with either FASLG or CASP10 mutations presented with typical ALPS manifestations and similar laboratory abnormalities and defective Fas-mediated apoptosis. Patients with the ALPS-sFAS classification are similar to ALPS-FAS patients, although this needs further study and longer follow-up. Individuals with other forms of ALPS may also be at an increased risk for lymphoma; however, further data are needed to provide a detailed risk assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1698882\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ALPS have a variety of laboratory findings, some of which are shared with other immunologic and hematologic disorders, but others that are unique to ALPS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/1,3,14-23\">",
"     1,3,14-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The signature laboratory abnormality unique to ALPS is the presence of",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    double-negative T cells (DNT cells) in peripheral blood or tissue specimens. Detected by flow cytometric immunophenotyping, these terminally differentiated in vivo-activated T cells are rare in healthy individuals and other immune-mediated (lymphoproliferative) disorders; typically they constitute less than 2 percent of the lymphocyte pool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link&amp;anchor=H12#H12\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\", section on 'Autoimmune lymphoproliferative syndrome (ALPS)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As part of the lymphoproliferative aspect of ALPS, other lymphocyte subsets are expanded as well. Immunophenotypically, these include",
"    <span class=\"nowrap\">",
"     gamma/delta-DNT",
"    </span>",
"    cells, CD8+CD57+ T cells, as well as HLA-DR+ T cells and B cells that express CD5. Not all lymphocyte subsets are expanded however, as patients show decreased numbers of CD4+CD25+ T cells and decreased numbers of CD27+ B cells. In rare patients, lymphopenia is observed (independent of immunosuppressive therapy), instead of the typical lymphocytosis.",
"   </p>",
"   <p>",
"    Lymph node pathology in typical cases shows paracortical expansion with",
"    <span class=\"nowrap\">",
"     immunoblasts/plasma",
"    </span>",
"    cells and DNT cells in interfollicular areas, florid follicular hyperplasia, and progressive transformation of germinal centers. Sinus histiocytosis is also occasionally observed.",
"   </p>",
"   <p>",
"    Other immunologic laboratory findings that are typical and unique to ALPS include abnormal Fas-mediated apoptosis in vitro and increased levels of vitamin B12 and IL-10 in",
"    <span class=\"nowrap\">",
"     serum/plasma.",
"    </span>",
"    There are also increased levels of soluble IL-18, CD25, CD27, CD30, and FasL, but these may or may not be specific for ALPS.",
"   </p>",
"   <p>",
"    Additional findings include increased levels of IgG, IgA, and IgE; normal or decreased concentrations of IgM; and the presence of a wide repertoire of autoantibodies (most often positive direct or indirect antiglobulin test, antiplatelet antibody, antineutrophil antibody, antiphospholipid antibody, antinuclear antibody, and rheumatoid factor). Autoantibodies are typically of the IgG subclass and of high-affinity, in contrast to naturally occurring autoantibodies of the same specificity that are low-affinity and IgM-derived.",
"   </p>",
"   <p>",
"    The immune system is largely intact, as far as T cell and NK cell functions are concerned. B cell function, as measured by antibody responses to infections and vaccinations, demonstrate normal responses to protein antigens, but reduced responses to polysaccharide antigens, although this is not uniformly the case.",
"   </p>",
"   <p>",
"    Hematologically, Coombs-positive hemolytic anemia with reticulocytosis, dyserythropoiesis, thrombocytopenia, neutropenia, and eosinophilia are observed in most patients, although often not at the time of ALPS diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699873\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ALPS is based upon clinical findings, laboratory abnormalities including defective",
"    <em>",
"     in vitro",
"    </em>",
"    Fas-mediated apoptosis, presence of",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    double-negative T (DNT) cells, and identification of mutations in genes relevant for the Fas pathway of apoptosis (",
"    <em>",
"     FAS",
"    </em>",
"    ,",
"    <em>",
"     FASLG",
"    </em>",
"    , and",
"    <em>",
"     CASP10",
"    </em>",
"    ). Molecular genetic testing of",
"    <em>",
"     FAS",
"    </em>",
"    ,",
"    <em>",
"     FASLG",
"    </em>",
"    , and",
"    <em>",
"     CASP10",
"    </em>",
"    is available clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699880\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A revised set of diagnostic criteria was published in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/23\">",
"     23",
"    </a>",
"    ]. A definitive diagnosis of ALPS is based upon the presence of both required criteria and one primary accessory criterion. A probable diagnosis is based upon the presence of both required criteria plus one secondary accessory criterion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699887\">",
"    <span class=\"h3\">",
"     Required criteria",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic (&gt;6 months) nonmalignant, noninfectious lymphadenopathy, splenomegaly, or both",
"     </li>",
"     <li>",
"      Elevated T cells that express the",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      T cell receptor but lack both CD4 and CD8",
"      <span class=\"nowrap\">",
"       (alpha/beta",
"      </span>",
"      double-negative T cells, or DNT cells) in the context of normal or elevated lymphocyte counts",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699895\">",
"    <span class=\"h3\">",
"     Primary accessory criteria",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Defective lymphocyte apoptosis (assay repeated at least once)",
"     </li>",
"     <li>",
"      Somatic or germline pathogenic mutations in",
"      <em>",
"       FAS",
"      </em>",
"      ,",
"      <em>",
"       FASLG",
"      </em>",
"      , or",
"      <em>",
"       CASP10",
"      </em>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699903\">",
"    <span class=\"h3\">",
"     Secondary accessory criteria",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated plasma levels of soluble FasL, IL-10, vitamin B12, or IL-18",
"     </li>",
"     <li>",
"      Typical immunohistologic findings as determined by an experienced hematopathologist (see",
"      <a class=\"local\" href=\"#H1698882\">",
"       'Laboratory findings'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Autoimmune cytopenias with elevated (polyclonal) IgG levels",
"     </li>",
"     <li>",
"      Positive family history",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699911\">",
"    <span class=\"h2\">",
"     Testing and classification strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proposed algorithm for the diagnostic workup for patients with suspected ALPS based upon the presence of required and accessory criteria, is outlined in the revised diagnostic criteria for ALPS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/23\">",
"     23",
"    </a>",
"    ]. Caution should be used regarding interpretation of laboratory data if the patient is, or in the recent past has been on,",
"    <span class=\"nowrap\">",
"     immunosuppressive/immunomodulating",
"    </span>",
"    therapy.",
"   </p>",
"   <p>",
"    The algorithm, which assumes that the presence of chronic nonmalignant lymphoproliferation and DNT cells has already been established, recommends the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, determine the presence of germline",
"      <em>",
"       FAS",
"      </em>",
"      mutation in unsorted cells obtained from blood or other tissues. The diagnosis of ALPS is established and classified as ALPS-FAS if a germline",
"      <em>",
"       FAS",
"      </em>",
"      mutation is identified.",
"     </li>",
"     <li>",
"      In the absence of a germline",
"      <em>",
"       FAS",
"      </em>",
"      mutation, the next step is to determine if biomarkers (IL-10, soluble FasL, vitamin B12) are elevated. If they are elevated, sorted DNT cells are assessed for somatic mutation in",
"      <em>",
"       FAS",
"      </em>",
"      . The diagnosis of ALPS is established and classified as ALPS-sFAS if a somatic",
"      <em>",
"       FAS",
"      </em>",
"      mutation is found. Of note, the absence of a positive family history is also suggestive of ALPS-sFAS.",
"     </li>",
"     <li>",
"      If the biomarkers are not elevated, evaluate for a genetic defect in caspase-10 or Fas ligand. The diagnosis of ALPS is established and classified as ALPS-CASP10 or ALPS-FASLG if germline mutations in either",
"      <em>",
"       CASP10",
"      </em>",
"      or",
"      <em>",
"       FASLG",
"      </em>",
"      are identified, respectively.",
"     </li>",
"     <li>",
"      If no genetic defects are identified, perform Fas-mediated apoptosis assay (repeat if necessary, keeping in mind that this assay may be normal if the patient is on concomitant immunosuppressive therapy). If abnormal, the diagnosis of ALPS is established and classified as ALPS-U.",
"     </li>",
"     <li>",
"      If Fas-mediated apoptosis is normal, consider examining",
"      <em>",
"       CASP10",
"      </em>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <em>",
"       FASLG",
"      </em>",
"      for somatic mutations using previously sorted DNT cells. Alternative diagnoses should also be considered at this point. (See",
"      <a class=\"local\" href=\"#H1699925\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699918\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis for pregnancies at increased risk for a",
"    <em>",
"     FAS",
"    </em>",
"    ,",
"    <em>",
"     FASLG",
"    </em>",
"    , or",
"    <em>",
"     CASP10",
"    </em>",
"    mutation is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis at approximately 15 to 18 weeks' gestation or chorionic villus sampling at approximately 10 to 12 weeks' gestation. The disease-causing allele(s) of an affected family member must be identified before prenatal testing can be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699925\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main considerations in the differential diagnosis are other immunodeficiency disorders characterized or complicated by lymphoproliferation, autoimmune disease (particularly autoimmune cytopenias), and lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/24\">",
"     24",
"    </a>",
"    ]. Evans syndrome is sometimes considered a specific entity. However, it should be regarded as a descriptive term, meaning the presence of ITP and AIHA, either concomitantly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sequentially. Even if a primary diagnosis cannot be made, Evans syndrome should be regarded as a constellation of manifestations of an underlying",
"    <span class=\"nowrap\">",
"     immunologic/hematologic",
"    </span>",
"    disorder (such as ALPS). In that context, primary immunodeficiency disorders can present with lymphoproliferation, including lymphoma, and autoimmune cytopenias. With this in mind, the differential diagnosis includes the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699932\">",
"    <span class=\"h2\">",
"     Common variable immunodeficiency disease (CVID)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder characterized by impaired B cell differentiation with defective immunoglobulin production. It is the most prevalent form of severe antibody deficiency affecting both children and adults, hence the term \"common.\" \"Variable\" refers to the heterogeneous clinical manifestations of this disorder, which include recurrent infections, chronic lung disease, autoimmune disorders, gastrointestinal disease, and a heightened susceptibility to lymphoma. The underlying cause of CVID is not known for most patients, although specific molecular defects have been identified in a subset of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From a clinical and immunologic standpoint, CVID can be roughly classified into two groups, depending upon the presence or absence of mature B cells in peripheral blood. Individuals with CVID who have mature B cells but absent or decreased memory B cells are at an increased risk for autoimmune disease that often targets blood cells and for chronic lymphoproliferation including lymphadenopathy, splenomegaly, and lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A reduction in memory B cells is also seen in some patients with ALPS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/27\">",
"     27",
"    </a>",
"    ]. CVID with present B cells should be regarded in the differential diagnosis of ALPS, while the variant characterized by low or absent B cells and generally low serum concentrations of immunoglobulins should not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699939\">",
"    <span class=\"h2\">",
"     Hyper IgM syndrome (HIGM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyper IgM syndrome (HIGM) is a group of genetic defects that cause deficiency of IgG, IgA, and IgM, with normal or elevated levels of IgM. HIGM can be X-linked (due to a defect in",
"    <em>",
"     CD40L",
"    </em>",
"    ) or autosomal recessive (due to defects in",
"    <em>",
"     CD40",
"    </em>",
"    ,",
"    <em>",
"     NEMO",
"    </em>",
"    ,",
"    <em>",
"     AICDA",
"    </em>",
"    , or",
"    <em>",
"     UNG",
"    </em>",
"    ). The shared features caused by these defects include recurrent bacterial infections such as otitis media, sinusitis, and pneumonias. Autoimmune hematologic disorders, including neutropenia, thrombocytopenia, and hemolytic anemia, are also found. Other complications may include lymphomas and other malignancies as well as gastrointestinal complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21001?source=see_link\">",
"     \"Hyperimmunoglobulin M syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H18#H18\">",
"     \"Combined immunodeficiencies\", section on 'Defects of NF-kappa-B regulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699946\">",
"    <span class=\"h2\">",
"     X-linked lymphoproliferative syndrome (XLP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked lymphoproliferative syndrome (XLP) is associated with an inappropriate immune response to Epstein-Barr virus (EBV) infection resulting in unusually severe and often fatal infectious mononucleosis, dysgammaglobulinemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphoproliferative disorders that are typically of B cell origin. XLP is caused by hemizygous mutations in SH2D1A. Lymphomas or other lymphoproliferative disease occur in approximately one-third of males with XLP, some of who have hypogammaglobulinemia or have survived an initial EBV infection. The lymphomas seen in individuals with XLP are typically high-grade B cell lymphomas, non-Hodgkin type, often extranodal, and often involve the intestine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33384?source=see_link\">",
"     \"X-linked lymphoproliferative disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699953\">",
"    <span class=\"h2\">",
"     Wiskott-Aldrich syndrome (WAS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wiskott-Aldrich syndrome is an X-linked disorder that typically manifests in infancy with thrombocytopenia, eczema, and recurrent bacterial and viral infections, particularly recurrent ear infections. At least 40 percent of males who survive the early complications develop one or more autoimmune conditions such as hemolytic anemia, immune thrombocytopenic purpura (ITP), immune-mediated neutropenia, arthritis, vasculitis of small and large vessels, and immune-mediated kidney and liver disease. Individuals with WAS, particularly those who have been exposed to EBV, have an increased risk of developing lymphomas, which often occur in unusual, extranodal locations such as the brain, lung, or gastrointestinal tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"     \"Wiskott-Aldrich syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699960\">",
"    <span class=\"h2\">",
"     Other rare disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few case reports of patients with mutations in the genes for caspase-8 (CASP8), neuroblastoma Ras viral oncogene homolog (NRAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/28\">",
"     28",
"    </a>",
"    ], or V-KI-RAS2 Kristen rat sarcoma viral oncogene homolog (KRAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] that have clinical features similar to ALPS. As part of the revised diagnostic criteria, these disorders have been separated from ALPS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H29#H29\">",
"     \"Combined immunodeficiencies\", section on 'Caspase-8 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699967\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoma without other manifestations of ALPS has been observed in families with ALPS-FAS. Thus, both B cell and T cell lymphoma should be considered in the differential diagnosis of ALPS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30279/abstract/12,31\">",
"     12,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1699418\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder characterized by defective lymphocyte homeostasis, resulting from defective Fas-mediated apoptosis. (See",
"      <a class=\"local\" href=\"#H1698604\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=see_link\">",
"       \"Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ALPS typically manifests in the first years of life. The three most common clinical manifestations are",
"      <span class=\"nowrap\">",
"       lymphadenopathy/splenomegaly/hepatomegaly,",
"      </span>",
"      autoimmune disease (cytopenias), and lymphoma. (See",
"      <a class=\"local\" href=\"#H1698840\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The signature laboratory abnormality unique to ALPS is the presence of T cells that express the",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      T cell receptor but lack both CD4 and CD8",
"      <span class=\"nowrap\">",
"       (alpha/beta",
"      </span>",
"      double-negative T cells, or DNT cells) in peripheral blood or tissue specimens. Other immunologic laboratory findings that are typical and unique to ALPS include abnormal Fas-mediated apoptosis",
"      <em>",
"       in vitro",
"      </em>",
"      , increased levels of IL-10 in",
"      <span class=\"nowrap\">",
"       serum/plasma,",
"      </span>",
"      and increased levels of vitamin B12. Hematologic findings include Coombs-positive hemolytic anemia with reticulocytosis, dyserythropoiesis, thrombocytopenia, neutropenia, and eosinophilia. (See",
"      <a class=\"local\" href=\"#H1698882\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ALPS is based upon clinical findings (lymphadenopathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      splenomegaly), laboratory abnormalities including defective",
"      <em>",
"       in vitro",
"      </em>",
"      Fas-mediated apoptosis, presence of",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      double-negative T (DNT) cells, and identification of mutations in genes relevant for the Fas pathway of apoptosis (",
"      <em>",
"       FAS",
"      </em>",
"      ,",
"      <em>",
"       FASLG",
"      </em>",
"      , and",
"      <em>",
"       CASP10",
"      </em>",
"      ). (See",
"      <a class=\"local\" href=\"#H1699873\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main considerations in the differential diagnosis are other immunodeficiency disorders characterized or complicated by lymphoproliferation, autoimmune disease (particularly autoimmune cytopenias), and lymphoma. These include common variable immunodeficiency (CVID), hyper IgM syndrome (HIGM), X-linked lymphoproliferative disease (XLP), and Wiskott-Aldrich syndrome (WAS). Both B cell and T cell lymphoma should also be considered in the differential diagnosis of ALPS. (See",
"      <a class=\"local\" href=\"#H1699925\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/1\">",
"      Bleesing JJ. Autoimmune lymphoproliferative syndrome (ALPS). Curr Pharm Des 2003; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/2\">",
"      Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol 2003; 15:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/3\">",
"      Bleesing JJ, Brown MR, Straus SE, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood 2001; 98:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/4\">",
"      Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood 2010; 115:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/5\">",
"      Rieux-Laucat F, Blach&egrave;re S, Danielan S, et al. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood 1999; 94:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/6\">",
"      Vaishnaw AK, Toubi E, Ohsako S, et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Arthritis Rheum 1999; 42:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/7\">",
"      Kanegane H, Vilela MM, Wang Y, et al. Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis. Pediatr Nephrol 2003; 18:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/8\">",
"      Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/9\">",
"      Rao VK, Carrasquillo JA, Dale JK, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol 2006; 81:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/10\">",
"      M&uuml;schen M, Rajewsky K, Kr&ouml;nke M, K&uuml;ppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol 2002; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/11\">",
"      Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/12\">",
"      Poppema S, Maggio E, van den Berg A. Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma 2004; 45:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/13\">",
"      Peter ME, Legembre P, Barnhart BC. Does CD95 have tumor promoting activities? Biochim Biophys Acta 2005; 1755:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/14\">",
"      Bleesing JJ. Sorting out the causes of ALPS. J Pediatr 2005; 147:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/15\">",
"      Lim MS, Straus SE, Dale JK, et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol 1998; 153:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/16\">",
"      Carter LB, Procter JL, Dale JK, et al. Description of serologic features in autoimmune lymphoproliferative syndrome. Transfusion 2000; 40:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/17\">",
"      Bleesing JJ, Brown MR, Dale JK, et al. TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol 2001; 100:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/18\">",
"      Lopatin U, Yao X, Williams RK, et al. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood 2001; 97:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/19\">",
"      Bleesing JJ, Brown MR, Novicio C, et al. A composite picture of TcR alpha/beta(+) CD4(-)CD8(-) T Cells (alpha/beta-DNTCs) in humans with autoimmune lymphoproliferative syndrome. Clin Immunol 2002; 104:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/20\">",
"      Maric I, Pittaluga S, Dale JK, et al. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol 2005; 29:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/21\">",
"      Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood 2009; 113:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/22\">",
"      Caminha I, Fleisher TA, Hornung RL, et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 2010; 125:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/23\">",
"      Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010; 116:e35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/24\">",
"      Teachey DT. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 2012; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/25\">",
"      Warnatz K, Denz A, Dr&auml;ger R, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 2002; 99:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/26\">",
"      Piqueras B, Lavenu-Bombled C, Galicier L, et al. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J Clin Immunol 2003; 23:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/27\">",
"      Rensing-Ehl A, Warnatz K, Fuchs S, et al. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. Clin Immunol 2010; 137:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/28\">",
"      Oliveira JB, Bid&egrave;re N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A 2007; 104:8953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/29\">",
"      Takagi M, Shinoda K, Piao J, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood 2011; 117:2887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/30\">",
"      Niemela JE, Lu L, Fleisher TA, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 2011; 117:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30279/abstract/31\">",
"      van der Werff ten Bosch J, Delabie J, B&ouml;hler T, et al. Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. Br J Haematol 1999; 106:1045.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16837 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30279=[""].join("\n");
var outline_f29_36_30279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1699418\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1698604\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1698840\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1698847\">",
"      Chronic nonmalignant lymphoproliferation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1698854\">",
"      Autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1698861\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1698868\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1698875\">",
"      Other ALPS genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1698882\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1699873\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699880\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1699887\">",
"      - Required criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1699895\">",
"      - Primary accessory criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1699903\">",
"      - Secondary accessory criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699911\">",
"      Testing and classification strategy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699918\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1699925\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699932\">",
"      Common variable immunodeficiency disease (CVID)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699939\">",
"      Hyper IgM syndrome (HIGM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699946\">",
"      X-linked lymphoproliferative syndrome (XLP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699953\">",
"      Wiskott-Aldrich syndrome (WAS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699960\">",
"      Other rare disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1699967\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1699418\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21001?source=related_link\">",
"      Hyperimmunoglobulin M syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=related_link\">",
"      Pathogenesis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33384?source=related_link\">",
"      X-linked lymphoproliferative disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_36_30280="Shutt suture punch";
var content_f29_36_30280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Shutt suture punch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30280=[""].join("\n");
var outline_f29_36_30280=null;
var title_f29_36_30281="Treatment and prognosis of adult T cell leukemia-lymphoma";
var content_f29_36_30281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of adult T cell leukemia-lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30281/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30281/contributors\">",
"     Masao Matsuoka, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30281/contributors\">",
"     Kensei Tobinai, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30281/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30281/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/36/30281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult T cell leukemia-lymphoma (ATL) is a peripheral T cell neoplasm associated with infection by the human T-lymphotropic virus, type I (HTLV-1). Although it is considered one of the highly aggressive T cell non-Hodgkin lymphoma (NHL) variants, the disease course is variable and sometimes quite indolent.",
"   </p>",
"   <p>",
"    Four clinical variants of ATL have been described: acute, lymphoma-type (lymphomatous), chronic and smoldering; these appear to have differing genomic alterations and varying clinical courses, and may require different treatment.",
"   </p>",
"   <p>",
"    The treatment of ATL is discussed here. The epidemiology, pathogenesis, clinical features, pathology, and diagnosis of ATL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, there are four clinical variants of ATL: acute, lymphoma-type, chronic, and smoldering [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These differ greatly in their presentation and prognosis. Therapy is usually offered to patients with acute, lymphoma-type, or unfavorable chronic type ATL while patients with typical chronic or smoldering ATL are observed initially. This is principally because conventional chemotherapy does not appear to improve the survival of patients with chronic or smoldering ATL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The five-year survival rate of patients with chronic and smoldering ATL was 47 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a retrospective evaluation of 26 patients with smoldering ATL reported that 14 (54 percent) were alive without tumor progression at median follow-up of 6.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/4\">",
"     4",
"    </a>",
"    ]. For those who died, the median time to transformation to a more aggressive variant was 38 months.",
"   </p>",
"   <p>",
"    In contrast, most patients with acute or lymphoma-type ATL have a survival without treatment measured in days to weeks. A brief description of the clinical variants of ATL is given below. This is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute &mdash; These patients present with systemic symptoms, organomegaly, lymphadenopathy, an elevated lactate dehydrogenase (LDH) level, and circulating malignant cells. Survival with treatment is measured in months to a year. Four-year survival rates are approximately 5 to 10 percent and median survival is 8 to 10 months when treated with regimens devised for advanced, aggressive NHL.",
"     </li>",
"     <li>",
"      Lymphoma-type &mdash; This variant is characterized by prominent lymphadenopathy without blood involvement. Prognosis is poor with a survival similar to that of patients with the acute variant.",
"     </li>",
"     <li>",
"      Chronic &mdash; These patients present with skin lesions, mild lymphadenopathy, and leukocytosis with an absolute lymphocytosis that may be stable for months to years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/5\">",
"       5",
"      </a>",
"      ]. Median survival is two to five years, however, there is a subgroup of patients with unfavorable chronic-type ATL which is defined by a low serum albumin, high LDH, or high blood urea nitrogen concentration. These patients have a poor prognosis similar to that of the acute and lymphoma variants.",
"     </li>",
"     <li>",
"      Smoldering &mdash; These patients are often asymptomatic except for frequent skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary lesions. They have normal blood lymphocyte counts with less than 5 percent circulating neoplastic cells and normal calcium levels. Median survival without treatment is approximately three years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation both determines the bulk of disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with ATL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes including calcium, LDH, albumin, uric acid, soluble interleukin-2 receptor, and flow cytometry for CD4, CD8, and CD25. Patients with risk factors should undergo testing for HIV.",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy or aspiration is recommended for all patients. Bone marrow involvement was detected in approximately 28 percent in one study mainly consisting of lymphoma-type ATL [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lumbar puncture is recommended for all patients with acute or lymphoma-type variants but may be performed at the start of therapy if intrathecal chemotherapy is a component of the treatment regimen. Cerebrospinal fluid should be sent for cytology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      flow cytometry.",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the neck, chest, abdomen and pelvis should be performed. This study provides critical information on the measurement of disease prior to treatment and aids in staging [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/9\">",
"       9",
"      </a>",
"      ]. Although the FDG-avidity of ATL is not well established, positron emission tomography (PET) scanning is recommended if it is possible prior to therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endoscopy of the upper gastrointestinal tract with biopsy should be considered for all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/10\">",
"       10",
"      </a>",
"      ]. Although GI tract involvement is more frequent in aggressive variants than indolent variants, a fraction of the latter still have GI tract involvement.",
"     </li>",
"     <li>",
"      A study of cardiac ejection fraction (eg, echocardiogram or MUGA) should be performed if anthracyclines are used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and women of child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Given the urgent need for treatment with ATL, options for women are limited, but men can often participate in sperm banking. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General approaches to the diagnostic work-up and staging of non-Hodgkin lymphoma are presented separately (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182687172\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute, lymphomatous, or unfavorable chronic type ATL progress quickly without treatment and have a median overall survival measured in months. Treatment of these variants has been challenging since the tumor cells have an intrinsic resistance to most chemotherapeutic agents and because the patients have an underlying immunocompromised state associated with their HTLV-1 infection. Cell-mediated immunity is impaired in ATL patients while humoral immunity remains intact.",
"   </p>",
"   <p>",
"    The greatest experience with ATL comes from the Japan Clinical Oncology Group (JCOG). The best treatment for these patients is unclear and patients should be enrolled in clinical trials whenever possible. However, for patients who are not eligible for a clinical trial or for those who do not wish to participate in a trial, we offer the following guidelines. Combination chemotherapy, as described in the next section, is the main treatment option [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Autologous hematopoietic cell transplantation (HCT) does not appear to be effective. Allogeneic HCT may be appropriate for patients with a related or unrelated donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Multiagent regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal chemotherapy combination for patients with ATL is unclear and many intensive regimens have been investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/3,12-17\">",
"     3,12-17",
"    </a>",
"    ]. Patients may initially respond to treatment with combination chemotherapy regimens devised for advanced, aggressive NHL, but relapses are common [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/18\">",
"     18",
"    </a>",
"    ]. The median survival time for patients with acute, lymphoma-type, or unfavorable chronic type ATL treated in prospective trials that employed multiagent chemotherapy has ranged from 5 to 13 months.",
"   </p>",
"   <p>",
"    Of those evaluated in prospective trials, the regimen that appears to result in the longest median survival is VCAP-AMP-VECP (also known as LSG15), which includes treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , ranimustine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31123?source=see_link\">",
"     vindesine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/11\">",
"     11",
"    </a>",
"    ]. The use of VCAP-AMP-VECP is supported by prospective phase II and III trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III randomized trial of 118 patients with poor prognosis ATL compared six courses of VCAP-AMP-VECP with eight courses of CHOP-14 (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      every 14 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/17\">",
"       17",
"      </a>",
"      ]. Both groups of patients were given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) support and intrathecal prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and prednisone. At a median follow-up of 10.9 months, the following results were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients treated with VCAP-AMP-VECP had a significantly higher rate of complete response plus complete response unconfirmed compared with those treated with CHOP-14 (40 versus 25 percent, respectively). Overall response did not differ between the two arms (72 and 66 percent, respectively).",
"     </li>",
"     <li>",
"      The three-year overall survival rate (without censoring patients who went on to transplantation) showed a trend that favored the VCAP-AMP-VECP arm (24 versus 13 percent).",
"     </li>",
"     <li>",
"      Only 32 percent of the patients on the VCAP-AMP-VECP arm and 49 percent of the patients on the CHOP arm were able to complete therapy as planned. Toxicities were more common in the VCAP-AMP-VECP arm including grade 4 neutropenia (98 versus 83 percent), grade 4 thrombocytopenia (74 versus 17 percent), grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      infection (32 versus 15 percent), and electrolyte disturbances.",
"     </li>",
"     <li>",
"      There were three treatment related deaths in the VCAP-AMP-VECP arm (two from sepsis, one from interstitial pneumonitis) and none in the CHOP-14 arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with acute, lymphoma-type, or unfavorable chronic type ATL should be treated with combination chemotherapy. Given a 10 to 25 percent risk for involvement of the central nervous system (CNS) at diagnosis or relapse, we recommend that all patients receive intrathecal chemotherapy for CNS prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The evidence supporting this recommendation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the use of VCAP-AMP-VECP plus intrathecal chemotherapy rather than other regimens of combination chemotherapy. This regimen requires six to eight months of weekly chemotherapy with G-CSF support. The trials supporting the use of this regimen enrolled patients up to the age of 69 years. The ranimustine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31123?source=see_link\">",
"     vindesine",
"    </a>",
"    used in this regimen are not available in some countries, including the United States. For patients treated by clinicians who do not have access to these agents, an acceptable alternative regimen is hyperfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (hyper-CVAD). While hyper-CVAD is frequently used to treat other forms of T cell lymphoma, there are limited data regarding the use of hyper-CVAD for the treatment of ATL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some investigators have reported anecdotal experiences suggesting the efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , the evidence supporting its efficacy is inadequate, and most patients with aggressive subtypes of ATL cannot be controlled with oral etoposide for a clinically meaningful duration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, VCAP-AMP-VECP plus intrathecal chemotherapy is associated with significant toxicity. Elderly patients (principally those older than 70 years of age) are less able to tolerate this aggressive regimen. Thus, for patients over 70 years old, we suggest the use of CHOP or CHOP-like regimens, based on the subgroup analysis of the phase III study described above [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Supportive factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with ATL requires close attention to the following issues that often surround chemotherapy administration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ATL are immunocompromised and are therefore at risk for potentially lethal opportunistic infections with organisms such as Pneumocystis jirovecii (previously carinii), Candida, cytomegalovirus, disseminated cryptococcus, and Strongyloides stercoralis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/3\">",
"       3",
"      </a>",
"      ]. We routinely administer oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) for Pneumocystis jiroveci pneumonia (PCP) prophylaxis.",
"      <span class=\"nowrap\">",
"       TMP/SMX",
"      </span>",
"      can be myelosuppressive and may synergize with chemotherapy to result in a more profound and longer nadir. As such, blood counts must be monitored during therapy. In addition, we administer antifungals to all patients receiving chemotherapy for ATL. Anti-strongyloides agents are given to patients with a past",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      present exposure to the parasite in the tropics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercalcemia, which can be severe, is one of the most significant complications in ATL patients. There is no routine prophylaxis given, but patients must be followed closely so that treatment can be initiated emergently. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"       \"Treatment of hypercalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physicians preparing to treat patients with one of the highly aggressive NHLs need to be aware that there is a significant risk of tumor lysis syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/24\">",
"       24",
"      </a>",
"      ]. This syndrome is best prevented via appropriate treatment with aggressive intravenous fluid hydration,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      , correction of any prior electrolyte disturbances and elements of reversible renal failure, as well as the provision of sufficient fluids to insure a high urine output (",
"      <a class=\"graphic graphic_table graphicRef57607 \" href=\"UTD.htm?22/10/22701\">",
"       table 2",
"      </a>",
"      ). This is most appropriately performed in a continuously monitored inpatient setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"       \"Uric acid renal diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712100#H21712100\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Treatment of established TLS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oncologic emergencies and treatment-related hematologic toxicities are common in the highly aggressive NHLs. The patient's physicians must always be alert to their potential presence, and be prepared to deal with them urgently and effectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Oncologic emergencies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182687009\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of antiviral agents in ATL is controversial. The HTLV-1 virus is thought to be in a latent state in patients with ATL and so antiviral agents, if active, would be expected to act through a mechanism other than antiviral activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/25\">",
"     25",
"    </a>",
"    ]. Small, prospective trials and retrospective analyses performed outside of Japan have evaluated the use of the antiviral agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (AZT) plus interferon alpha in the treatment of newly diagnosed or relapsed ATL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. Median survival times with this regimen have ranged from 6 to 18 months. Some of these trials included patients with less aggressive variants of ATL who would be expected to have a good prognosis without any treatment.",
"   </p>",
"   <p>",
"    A 2010 meta-analysis of AZT plus interferon-alpha incorporated data from 245 patients with acute (47 percent), chronic (7 percent), smoldering (4 percent), or lymphoma-type (42 percent) ATL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/33\">",
"     33",
"    </a>",
"    ]. For the 207 patients whose first-line therapy was recorded, the following five-year overall survival rates were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AZT plus interferon alpha (75 patients) &mdash; 46 percent",
"     </li>",
"     <li>",
"      Chemotherapy (77 patients) &mdash; 20 percent",
"     </li>",
"     <li>",
"      Chemotherapy followed by antiviral therapy (55 patients) &mdash; 12 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with acute, chronic, and smoldering ATL appeared to benefit from first-line antiviral therapy, whereas patients with lymphoma-type ATL did not. For patients with chronic or smoldering ATL, this combination was reported to result in 100 percent five-year survival. Based on the results of this retrospective analysis, the investigators suggested this combination regimen as the first-line therapy in leukemic subtypes of ATL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/34\">",
"     34",
"    </a>",
"    ]. While encouraging, we believe that this approach needs further prospective study before it can be widely applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both autologous and allogeneic hematopoietic cell transplantations (HCTs) have been attempted to improve outcomes in patients with ATL. Although experience is somewhat limited, autologous HCT does not appear to be of benefit due to frequent early relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/35\">",
"     35",
"    </a>",
"    ]. Allogeneic HCT offers a potential graft-versus-leukemia effect and may be considered for patients with an available donor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of small non-randomized studies have evaluated the role of myeloablative and nonmyeloablative allogeneic HCT in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/36,38-42\">",
"     36,38-42",
"    </a>",
"    ]. Treatment-related mortality was high, although long-term survival was achieved in some patients, with evidence of a graft-versus-HTLV-1 and a graft-versus-tumor effect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/40,43\">",
"     40,43",
"    </a>",
"    ]. After allogeneic HCT, provirus load was significantly decreased in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/40,44\">",
"     40,44",
"    </a>",
"    ], suggesting that anti-HTLV-1 immune response is enhanced in these patients. Phase II studies of nonmyeloablative and myeloablative allogeneic HCT are underway in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/3,45,46\">",
"     3,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective data are available from Japan regarding 386 patients with ATL who underwent allogeneic HCT from an HLA-matched related donor (154 patients), HLA-mismatched related donor (43 patients), unrelated marrow donor (99 patients), or unrelated cord blood donor (90 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/47\">",
"     47",
"    </a>",
"    ]. After a median follow-up of 41 months, the estimated three-year survival rate was 33 percent. Four factors were significantly associated with worse outcomes: age &gt;50 years, male sex, disease not in complete remission at the time of HCT, and unrelated donor source.",
"   </p>",
"   <p>",
"    In another analysis of this patient cohort, patients who developed either mild to moderate (grade",
"    <span class=\"nowrap\">",
"     1/2)",
"    </span>",
"    or severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    acute graft-versus-host disease (GVHD) had a significantly lower disease-related mortality when compared with those patients who did not develop GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with grade",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    GVHD had superior overall survival than those without GVHD (hazard ratio [HR] 0.65; 95% CI 0.45-0.93). In contrast, survival was inferior in patients with grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    GVHD (HR 1.64; 95% CI 1.10-2.42), likely due to an increase in treatment-related mortality (HR 3.50; 95% CI 2.01-6.11).",
"   </p>",
"   <p>",
"    In another analysis, this cohort was expanded to include 586 patients with ATL who underwent allogeneic HCT between 1992 and 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/49\">",
"     49",
"    </a>",
"    ]. For the 280 patients who underwent myeloablative conditioning, median overall survival (OS) and estimated three-year survival were 9.5 months (95% CI 6.7-18.0 months) and 39 percent (33 to 45 percent), respectively. Corresponding values for the 306 patients who underwent reduced intensity conditioning were 10 months (7.2 to 14.0 months) and 34 percent (29 to 40 percent), respectively. When compared with myeloablative conditioning, reduced intensity conditioning was associated with a trend towards less treatment-related mortality (HR 0.786; 95% CI 0.538-1.148), but greater leukemia-related mortality (HR 1.579; 95% CI 1.080-2.308).",
"   </p>",
"   <p>",
"    Another retrospective analysis included 40 patients with acute or lymphoma-type ATL who had undergone allogeneic HCT either as part of their initial therapy or at relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/36\">",
"     36",
"    </a>",
"    ]. All but one of the patients was treated with a myeloablative conditioning regimen. At the time of transplant, 15 were in CR, 13 in PR, 3 had stable disease, and 9 had progressive disease. Of the patients evaluable after HCT, all but one achieved a CR. The median survival time of all cases after HCT was 9.6 months. There were 16 deaths related to transplant. The three-year rates of overall survival and relapse-free survival were 45 and 34 percent, respectively. Acute and chronic graft-versus-host disease developed in 26 and 15 patients, respectively. Among the 10 patients who relapsed after HCT, five were able to achieve a second CR. Three of these CRs were obtained by reduction or cessation of immunosuppressive therapy alone suggesting a graft-versus-ATL effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned treatment of ATL, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse.",
"   </p>",
"   <p>",
"    Patients with ATL are immunocompromised and are therefore at risk for potentially lethal opportunistic infections with organisms such as Pneumocystis jirovecii (previously carinii), Candida, cytomegalovirus, and Strongyloides stercoralis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/3\">",
"     3",
"    </a>",
"    ]. While prophylaxis for such infections is generally given, clinicians need to consider these organisms when patients decompensate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"     \"Strongyloidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"     \"Diagnosis of cytomegalovirus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). The post-treatment imaging study of choice in patients remains computed tomography (CT). Although positron emission tomography (PET) scans have not been prospectively validated in patients with ATL, we perform a combined",
"    <span class=\"nowrap\">",
"     PET/CT,",
"    </span>",
"    if available.",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and CT scan, disease response is determined using the Japan Clinical Oncology Group (JCOG) response criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response is defined as the disappearance of all clinical and radiographic evidence of disease and the normalization of LDH level for at least four weeks. As carriers of HTLV-1 frequently have abnormal circulating lymphocytes, some abnormal lymphocytes can be present as long as they account for less than 5 percent of the total circulating lymphocytes. Some institutions do not require LDH normalization for the determination of complete response since there are other factors that could lead to its elevation, however, eliminating LDH from the response evaluation may overestimate the response rate.",
"     </li>",
"     <li>",
"      Partial response is a reduction in measurable disease by at least 50 percent with a more than 75 percent reduction in the absolute abnormal lymphocyte count for at least four weeks without the development of new lesions or disease progression. LDH must have decreased to less than 1.5 of the normal upper limit.",
"     </li>",
"     <li>",
"      Progressive disease is an at least 50 percent increase in the size of measurable disease or the appearance of new lesions during treatment.",
"     </li>",
"     <li>",
"      Stable disease includes those patients not achieving a CR, PR, or PD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who fail to obtain a complete response are treated as refractory disease. This is discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Treatment of recurrent or refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. Our approach is based upon the following general understandings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of relapses occur during the first year after completion of treatment.",
"     </li>",
"     <li>",
"      Relapses are usually symptomatic and are rarely identified solely on the basis of routine imaging.",
"     </li>",
"     <li>",
"      If a relapse is picked up a few weeks earlier because of more intense monitoring, it is unlikely to improve outcome.",
"     </li>",
"     <li>",
"      When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"       \"Radiation-related risks of imaging studies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits monthly during the first year, every two months during the second year, and every three months starting two years after complete response. At these visits, we perform a history and physical examination, complete blood count with differential, evaluation of the peripheral smear, chemistries, LDH, and flow cytometry for CD4, CD8, and CD25 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is recommended that relapsed disease suggested by changes on imaging be confirmed by biopsy. As such, a biopsy is recommended to document relapsed disease before proceeding to salvage therapy.",
"   </p>",
"   <p>",
"    In some patients with ATL relapse occurs as the appearance of leukemic cells in the peripheral blood alone. In addition, it is sometimes difficult to recognize leukemic cells by morphology alone. In such situations, flow cytometry of the peripheral blood mononuclear cells, especially evaluating the T4:T8 ratio, is easily performed and effective for estimating the leukemic cell kinetics in the peripheral blood. In particular, since ATL cells show a characteristic phenotype that is both CD4 and CD25 positive, flow cytometry can be performed in most cases to identify leukemic cells in the peripheral blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little information on the treatment of recurrent or refractory ATL and patients should be referred for enrollment in clinical trials. Areas of investigation include the use of antiviral agents or antibody therapy. Patients who have undergone allogeneic hematopoietic cell transplantation (HCT) may respond to withdrawal of immunosuppression or immunotherapy with donor lymphocyte infusion (DLI). (See",
"    <a class=\"local\" href=\"#H182687009\">",
"     'Antiviral therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ATL cells express CCR4 on the surface [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/51\">",
"     51",
"    </a>",
"    ]. A defucosylated humanized anti-CCR4 antibody (mogamulizumab) has been reported to be effective to ATL cases and has been approved for use in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A multicenter phase II trial evaluated the use of mogamulizumab monotherapy in 28 patients with relapsed acute (52 percent), lymphomatous (22 percent), or chronic (26 percent) ATL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/53\">",
"     53",
"    </a>",
"    ]. Toxicity was mostly mild to moderate with the most common toxicities being infusion reactions (89 percent) and rash (63 percent). The overall response rate was 50 percent (29 percent complete) and median progression-free and overall survival of 5.2 and 13.7 months, respectively.",
"   </p>",
"   <p>",
"    Limited experience with the anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. There has also been interest in the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    with or without interferon alpha and in the use of all-trans retinoic acid (tretinoin) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/31,56-58\">",
"     31,56-58",
"    </a>",
"    ]. Other new agents for the potential application to the treatment of ATL include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/43/29366?source=see_link\">",
"     pralatrexate",
"    </a>",
"    (anti-folate),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    (proteasome inhibitor), forodesine (purine nucleoside phosphorylase inhibitor), histone deacetylase inhibitor, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the efficacy of radiation therapy in patients with ATL. A retrospective analysis of 10 consecutive patients with relapsed or refractory ATL treated with radiation therapy (mean 35.4 Gy; range 12 to 60 Gy) reported that all patients had an at least partial response with 40 percent attaining a complete response within the treatment field [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/59\">",
"     59",
"    </a>",
"    ]. Toxicity was generally mild to moderate and included cutaneous reactions, mucositis, and ocular toxicity. Radiation therapy may provide palliation of patients who have symptoms related to a single disease site.",
"   </p>",
"   <p>",
"    In a retrospective analysis of 35 patients with relapsed or refractory ATL following allogeneic HCT, the median time to relapse was less than four months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/37\">",
"     37",
"    </a>",
"    ]. The median survival time following relapse was 6.2 months and 19 percent of patients were alive at three years. A complete remission (CR) was attained in 2 of 29 patients following withdrawal of immunosuppression, and in 4 of 9 patients following DLI with or without prior cytoreductive therapy. Six patients had discontinued immunosuppressive therapy prior to relapse. Of these, the three with local recurrence attained a CR with cytoreductive therapy, while the three with systemic recurrence progressed despite cytoreductive therapy. A worsening of graft-versus-host disease (GVHD) was seen in 6 of 9 patients receiving DLI. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25492074\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described separately, there are four clinical variants of ATL: acute, lymphoma-type, chronic, and smoldering. These differ greatly in their presentation and prognosis. The clinical course of acute and lymphoma-type ATL is aggressive with survival without treatment measured in months. In contrast, most cases of chronic or smoldering ATL are more indolent with survival without treatment measured in years. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prognostic indices used for other non-Hodgkin lymphomas, such as the International Prognostic Index, are not very useful in this patient population, largely because the vast majority of patients would be classified as having intermediate- or high-risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/60\">",
"     60",
"    </a>",
"    ]. As such, efforts have been made to develop and validate a prognostic index specific for patients with acute or lymphoma-type ATL.",
"   </p>",
"   <p>",
"    A retrospective Japanese study of 807 patients with newly diagnosed acute or lymphoma-type ATL diagnosed between 2000 and 2009 randomly divided subjects into two groups that were used to create and validate a prognostic index for acute and lymphoma-type ATL (the ATL-PI) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30281/abstract/60\">",
"     60",
"    </a>",
"    ]. The median survival was 7.7 months overall. A point-based system was developed using the presence or absence of the following markers of poor outcome in the training group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ann Arbor stage III or IV &mdash; 2 points",
"     </li>",
"     <li>",
"      Eastern Cooperative Oncology Group (ECOG) Performance status &ge;2 &mdash; 1 point",
"     </li>",
"     <li>",
"      Age &gt;70 years &mdash; 1 point",
"     </li>",
"     <li>",
"      Serum albumin &lt;3.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      &mdash; 1 point",
"     </li>",
"     <li>",
"      Soluble interleukin-2 receptor (IL-2R) &gt;20,000",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      &mdash; 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total scores ranged from zero to six. This prognostic model separated the validation group into three populations with different outcomes: high (5 or 6 points), intermediate (3 or 4 points), and low (0, 1, or 2 points) risk groups that had median survival times of 4.6, 7.0, and 16.2 months, respectively. Corresponding rates of overall survival at two years were 6, 17, and 37 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult T cell leukemia-lymphoma (ATL) is a peripheral T cell neoplasm associated with infection by the human T-lymphotropic virus, type I (HTLV-1). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are four clinical variants of ATL: acute, lymphoma-type, chronic, and smoldering which differ greatly in their presentation and prognosis. Therapy is usually offered to patients with acute, lymphomatous, or unfavorable chronic type ATL while patients with typical chronic or smoldering ATL are observed initially. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretreatment evaluation both determines the bulk of disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform laboratory studies, unilateral bone marrow biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aspiration, lumbar puncture, cardiac function evaluation, and imaging in all patients. Fertility counseling should be offered to patients in child-bearing years. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best treatment for these patients is unclear and patients should be enrolled in clinical trials whenever possible. However, for patients who are not eligible for a clinical trial or for those who do not wish to participate in a trial, we offer the following guidelines:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients with acute, lymphoma-type, or unfavorable chronic type ATL require treatment. We recommend that these patients also receive intrathecal chemotherapy for CNS prophylaxis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest the use of VCAP-AMP-VECP rather than other regimens of combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Data regarding the use of antiviral therapy for acute and chronic variants are insufficient. VCAP-AMP-VECP contains agents that are not available in some countries, including the United States. For patients treated by clinicians that do not have access to these agents, an acceptable alternative regimen is hyperfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (hyper-CVAD), although its evidence is insufficient. For older patients or those with comorbidities that exclude VCAP-AMP-VECP as an option, we suggest the use of CHOP or CHOP-like regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Multiagent regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allogeneic HCT offers a potential graft-versus-leukemia effect and may be considered for patients with an available donor. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physicians preparing to treat patients with ATL need to be aware that hypercalcemia is a frequent complication and that there is a significant risk of tumor lysis syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"       \"Uric acid renal diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712100#H21712100\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Treatment of established TLS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After completion of the initially planned treatment of ATL, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ATL are immunocompromised and are therefore at risk for potentially lethal opportunistic infections with organisms such as Pneumocystis jirovecii (previously carinii), Candida, cytomegalovirus, and Strongyloides stercoralis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"       \"Strongyloidiasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"       \"Diagnosis of cytomegalovirus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"       \"Overview of Candida infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is little information on the treatment of recurrent or refractory ATL and patients should be referred for enrollment in clinical trials whenever possible. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment of recurrent or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/1\">",
"      Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/2\">",
"      Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/3\">",
"      Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol 2008; 80:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/4\">",
"      Ishitsuka K, Ikeda S, Utsunomiya A, et al. Smouldering adult T-cell leukaemia/lymphoma: a follow-up study in Kyushu. Br J Haematol 2008; 143:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/5\">",
"      Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010; 115:4337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/6\">",
"      Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009; 27:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/7\">",
"      Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/8\">",
"      Suzumiya J, Ohshima K, Tamura K, et al. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol 2009; 20:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/9\">",
"      Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008; 111:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/10\">",
"      Utsunomiya A, Hanada S, Terada A, et al. Adult T-cell leukemia with leukemia cell infiltration into the gastrointestinal tract. Cancer 1988; 61:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/11\">",
"      Tobinai K. Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park) 2009; 23:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/12\">",
"      Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988; 6:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/13\">",
"      Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 1988; 6:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/14\">",
"      Tobinai K, Shimoyama M, Minato K, et al. Japan Clinical Oncology Group trial of second-generation \"LSG4 protocol\" in aggressive lymphoma including ATL: prognostic factors and a predictive model (abstract). Proc Am Soc Clin Oncol 1994; 13:378a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/15\">",
"      Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003; 77:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/16\">",
"      Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/17\">",
"      Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25:5458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/18\">",
"      Yamada Y, Kamihira S, Amagasaki T, et al. Adult T cell leukemia with atypical surface phenotypes: clinical correlation. J Clin Oncol 1985; 3:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/19\">",
"      Teshima T, Akashi K, Shibuya T, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer 1990; 65:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/20\">",
"      Dungerwalla M, Osuji N, Waldman AD, et al. Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia. Br J Haematol 2005; 130:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/21\">",
"      Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin Lymphoma 2003; 4:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/22\">",
"      Matsushita K, Matsumoto T, Ohtsubo H, et al. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leuk Lymphoma 1999; 36:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/23\">",
"      Kojima H, Hori M, Shibuya A, et al. Successful treatment of a patient with adult T-cell leukemia by daily oral administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral DNA revealed by the polymerase chain reaction method. Cancer 1993; 72:3614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/24\">",
"      Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/25\">",
"      Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005; 24:6047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/26\">",
"      Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001; 113:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/27\">",
"      Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/28\">",
"      White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001; 40:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/29\">",
"      Hermine O, Allard I, L&eacute;vy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002; 3:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/30\">",
"      Ratner L, Harrington W, Feng X, et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One 2009; 4:e4420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/31\">",
"      Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009; 113:6528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/32\">",
"      Hodson A, Crichton S, Montoto S, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol 2011; 29:4696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/33\">",
"      Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010; 28:4177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/34\">",
"      Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood 2011; 118:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/35\">",
"      Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant 1999; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/36\">",
"      Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 2005; 19:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/37\">",
"      Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood 2013; 121:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/38\">",
"      Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/39\">",
"      Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol 2003; 120:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/40\">",
"      Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005; 105:4143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/41\">",
"      Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007; 40:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/42\">",
"      Yonekura K, Utsunomiya A, Takatsuka Y, et al. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/43\">",
"      Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 2004; 64:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/44\">",
"      Choi I, Tanosaki R, Uike N, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant 2011; 46:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/45\">",
"      Tanosaki R, Uike N, Utsunomiya A, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 2008; 14:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/46\">",
"      Tobinai K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Semin Hematol 2010; 47 Suppl 1:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/47\">",
"      Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010; 116:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/48\">",
"      Kanda J, Hishizawa M, Utsunomiya A, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 2012; 119:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/49\">",
"      Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 2012; 120:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/50\">",
"      Yasuda N, Lai PK, Ip SH, et al. Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 1988; 71:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/51\">",
"      Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002; 99:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/52\">",
"      Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/53\">",
"      Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/54\">",
"      Mone A, Puhalla S, Whitman S, et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. Blood 2005; 106:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/55\">",
"      Ravandi F, Faderl S. Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res 2006; 30:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/56\">",
"      Ishitsuka K, Suzumiya J, Aoki M, et al. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica 2007; 92:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/57\">",
"      Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/58\">",
"      Maeda Y, Yamaguchi T, Hijikata Y, et al. Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia. J Cancer Res Clin Oncol 2008; 134:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/59\">",
"      Simone CB 2nd, Morris JC, Stewart DM, et al. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Blood 2012; 120:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30281/abstract/60\">",
"      Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 2012; 30:1635.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4736 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30281=[""].join("\n");
var outline_f29_36_30281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182687172\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Multiagent regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Supportive factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182687009\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25492074\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4736\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4736|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/10/22701\" title=\"table 2\">",
"      TLS risk stratification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_36_30282="Treatment of male sexual dysfunction";
var content_f29_36_30282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of male sexual dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30282/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30282/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30282/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30282/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30282/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/36/30282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/36/30282/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/36/30282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major forms of male sexual dysfunction are erectile dysfunction, ejaculatory dysfunction, and decreased libido. Erectile dysfunction is a common problem in men over the age of 40 due to hormonal abnormalities, medications, psychological problems, neurologic disease, or vascular insufficiency. Men with this disorder experience significant psychological distress, which improves if treatment successfully restores erectile function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/1\">",
"     1",
"    </a>",
"    ]. Premature ejaculation may be another troublesome form of sexual dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of male sexual dysfunction is reviewed here. Erectile physiology and the major causes of erectile dysfunction are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines from the American Urological Association (AUA) have been published for the treatment of erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/3\">",
"     3",
"    </a>",
"    ] and premature ejaculation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/2\">",
"     2",
"    </a>",
"    ]. The American College of Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/4\">",
"     4",
"    </a>",
"    ] and The American Association of Clinical Endocrinologists have also issued treatment guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the treatment of male sexual dysfunction is to determine the etiology. Certain clues in the history and appropriate laboratory testing can usually establish the primary cause (",
"    <a class=\"graphic graphic_table graphicRef61756 \" href=\"UTD.htm?11/45/11995\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erectile dysfunction and cardiovascular disease share many risk factors, and their pathophysiology is mediated through endothelial dysfunction. Cardiovascular disease and its risk factors increase the risk for later erectile dysfunction (ED); on the other hand, erectile dysfunction may be an early warning sign of future cardiovascular events (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link&amp;anchor=H189242040#H189242040\">",
"     \"Overview of male sexual dysfunction\", section on 'Association with cardiovascular disease'",
"    </a>",
"    ). Lifestyle modifications such as diet and exercise, in addition to reducing cardiovascular risk factors, may improve ED as well. Cardiovascular risk factor reduction with pharmacotherapy may also improve ED.",
"   </p>",
"   <p>",
"    Therapy of men with erectile dysfunction is aimed at restoration of the two vital sexual functions: the capacity to acquire and sustain penile erections; and the reactivation of libido. Optimal treatment varies with the cause of the erectile dysfunction (",
"    <a class=\"graphic graphic_table graphicRef80719 graphicRef53269 \" href=\"UTD.htm?4/44/4815\">",
"     table 2A-B",
"    </a>",
"    ): Phosphodiesterase-5 (PDE-5) inhibitors, penile self-injection programs with vasoactive drugs, vacuum erection devices, or penile prostheses allow many men with vasculogenic, neurogenic, or psychogenic erectile dysfunction to acquire and maintain erections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For first-line therapy, we recommend the phosphodiesterase inhibitors because of their efficacy, ease of use, and favorable side effect profile.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      appear to be equally effective, but tadalafil has a longer duration of action. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacotherapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of drug'",
"      </a>",
"      below.) Phosphodiesterase inhibitors are",
"      <strong>",
"       contraindicated in men taking nitrates",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      For second-line therapy, we recommend consideration of penile self-injectable drugs, intraurethral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"       alprostadil",
"      </a>",
"      , and vacuum devices. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Penile self-injection'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H29\">",
"       'Vacuum-assisted erection devices'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Surgical implantation of a penile prosthesis should be reserved for men who cannot use or who have not responded to first- and second-line therapies. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Penile prostheses'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For men with sexual dysfunction and low serum testosterone levels, ie, hypogonadism, testosterone replacement therapy should be the initial treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"       \"Testosterone treatment of male hypogonadism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychotherapy alone or in combination with psychoactive drugs may be helpful in men whose erectile dysfunction is caused by depression or anxiety. In addition, alpha adrenergic blocking agents such as yohimbine hydrochloride have enjoyed some popularity as a remedy for men with psychogenic erectile dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"       \"Overview of male sexual dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In obese men with erectile dysfunction, weight loss and increased physical activity are associated with an improvement in erectile function in about one third of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72305449\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR RISK FACTOR REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, erectile dysfunction and cardiovascular disease share many risk factors, and their pathophysiology is mediated through endothelial dysfunction. Cardiovascular disease and its risk factors increase the risk for later erectile dysfunction (ED); conversely, erectile dysfunction may be an early warning sign of future cardiovascular events. Cardiovascular risk factor reduction, by either lifestyle modification or pharmacotherapy, appears to improve erectile dysfunction. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifestyle modifications such as diet and exercise have improved ED in studies of men with hypertension, diabetes, or the metabolic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of four randomized trials of lifestyle modification interventions in 597 men with ED demonstrated statistically significant improvement in sexual function [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Statins improved the response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      in two studies of men with dyslipidemia and ED [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72305547\">",
"    <span class=\"h2\">",
"     Phosphodiesterase 5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with erectile dysfunction, treatment options now include three phosphodiesterase-5 (PDE-5) inhibitors:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    . All act to increase intracavernosal cyclic GMP levels, and each one has been proven to be effective in restoring erectile function, allowing for satisfactory sexual intercourse in many men with erectile dysfunction. However, PDE-5 inhibitors will not work without sufficient environmental and psychological cues that result in sufficient sexual arousal and stimulation to initiate the physiological changes in the penis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    (Viagra) was the first orally administered treatment of proven efficacy for erectile dysfunction. Taken one hour before planned sexual intercourse, it is effective for a wide range of disorders causing erectile dysfunction. Nevertheless, it should not be prescribed before performing a systematic assessment of the cause of erectile dysfunction, including a history and physical examination and when appropriate, measurement of serum testosterone, prolactin, and TSH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and other PDE-5 inhibitors is based upon the role of nitric oxide-induced vasodilation (which is mediated by cyclic GMP) in initiating and maintaining an erection. Detumescence is associated with catabolism of cyclic GMP by type 5 phosphodiesterase. PDE-5 inhibitors act by blocking the latter enzyme and as a result increase both the number and duration of erections in men with erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link&amp;anchor=H2095400#H2095400\">",
"     \"Overview of male sexual dysfunction\", section on 'Role of blood flow and nitric oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a dose-escalation study of 25 to 100 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    in 532 men with organic (70 percent), psychogenic (11 percent), or mixed erectile dysfunction (18 percent), 69 percent of all attempts at sexual intercourse were successful in the men who took sildenafil compared to 22 percent of those who took placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/14\">",
"     14",
"    </a>",
"    ]. All do not respond to the drug as well, however. Only 56 percent of diabetic men have improved erections with sildenafil [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38341?source=see_link\">",
"     \"Erectile dysfunction in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In men with prostate cancer who have undergone prostatectomy or radiation therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    appears to be effective in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/16\">",
"     16",
"    </a>",
"    ] (more effective in those who had a nerve-sparing operation) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H683372924#H683372924\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Nerve-sparing approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A man's sexual capability can be measured using the International Index of Erectile Function (IIEF). Survey scores of men with erectile dysfunction (ED) are significantly lower than normal men. IIEF scores remain low in placebo-treated men but the IIEF scores of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    -treated men are comparable to normal healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/18\">",
"     18",
"    </a>",
"    ]. This is true even for men who have multiple factors contributing to their ED. A short form of the IIEF (the IIEF-5 or Sexual Health Inventory for Men [SHIM]) is a brief, more easily administered and practical diagnostic tool in a clinical practice setting.",
"   </p>",
"   <p>",
"    In a quantitative meta-analysis of 27 trials in 6659 men with erectile dysfunction, a higher percentage of successful sexual intercourse was achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    compared with placebo (57 versus 21 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of exogenous testosterone to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    therapy may be useful in men with serum total testosterone concentrations &lt;400",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    who do not respond to sildenafil alone. This was illustrated in a study of 75 such patients who were randomly assigned to receive daily testosterone gel (5",
"    <span class=\"nowrap\">",
"     gm/day)",
"    </span>",
"    or placebo in addition to sildenafil [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/20\">",
"     20",
"    </a>",
"    ]. A greater improvement in erectile function (as measured by the IIEF) was observed in the testosterone-sildenafil group when compared with placebo. Although serum total and free testosterone concentrations increased in the testosterone-sildenafil group, no correlation was seen between testosterone levels and erectile function. The clinical implications of these findings are unclear, as the lower limit of normal for most total testosterone assays is &lt;280 to 300",
"    <span class=\"nowrap\">",
"     ng/dL.",
"    </span>",
"    Therefore, many of the men in this study were not truly hypogonadal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;For maximum effectiveness,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    should be taken orally about one hour before a planned sexual encounter. The initial dose should be 50 mg, and it should be reduced to 25 mg if side effects occur. If, on the other hand, it is well tolerated but the erectile response is not fully satisfactory, the dose can be increased to 100 mg. The duration of action is approximately four hours (",
"    <a class=\"graphic graphic_table graphicRef80719 \" href=\"UTD.htm?23/9/23710\">",
"     table 2A",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    is associated with a variety of cardiovascular effects, which are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link&amp;anchor=H18#H18\">",
"     \"Sexual activity in patients with heart disease\", section on 'Sildenafil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      is a vasodilator that lowers the blood pressure by about 8 mmHg; this change typically produces no symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      and nitrates can lead to severe hypotension (eg, more than",
"      <span class=\"nowrap\">",
"       50/25",
"      </span>",
"      mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/22\">",
"       22",
"      </a>",
"      ] and syncope. As a result, sildenafil is",
"      <strong>",
"       contraindicated",
"      </strong>",
"      in patients taking nitrates of any form, regularly or intermittently. If a man who has taken sildenafil has an acute ischemic syndrome, nitrates should not be prescribed within 24 hours (or longer in patients with renal or hepatic dysfunction).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      has been associated with myocardial infarction and sudden death. However, since sexual activity is also associated with these complications, case reports of MI in association with sildenafil may have been unrelated to the drug. Consistent with this hypothesis are the results of extensive postmarketing surveillance, as well as a meta-analysis, which have failed to demonstrate a significant association between sildenafil and cardiac events [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/19,21\">",
"       19,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      does not appear to have adverse effects on coronary hemodynamics, even in men with either stable or severe coronary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. These data support the positions of the Second Princeton Consensus Panel and a consensus statement from the American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association that a PDE-5 inhibitor is safe for men with stable coronary artery disease who are not taking nitrates [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The vasodilator properties of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      may have an adverse effect in some patients with a hypertrophic cardiomyopathy; the decrease in preload and afterload can increase the outflow obstruction, culminating in an unstable hemodynamic state [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sexual activity in patients with heart disease, including the management of erectile dysfunction, is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"     \"Sexual activity in patients with heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha adrenergic antagonists, which are commonly used for the treatment of benign prostatic hyperplasia, may cause symptomatic hypotension when taken in combination with PDE-5 inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     Tamsulosin",
"    </a>",
"    is the least likely to cause orthostatic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current labeling for all three PDE-5 inhibitors recommends that patients should be stable on alpha blocker therapy prior to initiating a PDE-5 inhibitor (which should then be started at the lowest recommended dose). Conversely, in patients already taking a PDE-5 inhibitor, alpha blocker therapy should be initiated at the lowest dose.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    should also be avoided in patients taking drugs that can prolong the half-life of sildenafil by blocking CYP3A4 (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , protease inhibitors, and grapefruit juice); if used, the potential adverse effects should be stressed with the patient and sildenafil should be started at a dose of 25 mg rather than the 50 mg dose. On the other hand, drugs that induce CYP3A4 such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    can be expected to reduce the effectiveness of a dose of sildenafil.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Visual effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    acts by inhibiting type 5 phosphodiesterase, it can affect the retina via weak inhibition of type 6 phosphodiesterase, which is required for the transformation of light into electrical signals. In a brief report of five normal men, a single 100 mg dose of sildenafil caused changes in the electroretinogram one hour later that were completely reversible at six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/31\">",
"     31",
"    </a>",
"    ]. There were no changes in visual acuity, visual fields, or visual-evoked potentials.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    also causes blue vision in approximately 3 percent of men. This effect lasts two to three hours and disappears spontaneously.",
"   </p>",
"   <p>",
"    Rare cases (23 cases since 1998) of nonarteritic anterior ischemic optic neuropathy (NAION) have been reported in men taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/32\">",
"     32",
"    </a>",
"    ]. Most of these cases occurred in men with underlying autonomic or vascular risk factors. NAION shares a number of risk factors with erectile dysfunction: age over 50, hypertension, dyslipidemia, and diabetes. Therefore, it is unclear whether NAION in these patients is due to their underlying vascular risk factors, anatomic defects, or use of sildenafil. However, the United States Food and Drug Administration has ordered that warnings be added to labeling for sildenafil, tadalafil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    to reflect this potential risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H14#H14\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Phosphodiesterase-5 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    on visual function are unknown. At this time, monitoring of visual function does not appear to be necessary in the average man without retinal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are no clinical data on the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    in men with retinitis pigmentosa (a minority of whom have genetic disorders of retinal phosphodiesterase), the manufacturer recommends caution in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    use have been associated with rare reports (n = 29) of sudden hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/35\">",
"     35",
"    </a>",
"    ]. Although no causal relationship has been demonstrated, the US Food and Drug Administration has approved labeling changes for all three drugs to include this potential risk. The hearing loss was temporary in approximately one-third of patients, and ongoing (or unknown) in the remaining two-thirds at the time of the FDA report.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    are related to its vasodilatory properties and are similar to those induced by nitrates. These include headache, lightheadedness, dizziness, flushing, distorted vision, and, in some cases, syncope. In the meta-analysis described above, adverse events with sildenafil included flushing, headaches, dyspepsia, and visual disturbances in 12, 11, 5, and 3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Recreational use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    treatment is associated with a marked reduction in the post-ejaculatory refractory time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/36\">",
"     36",
"    </a>",
"    ], men are capable of having a second erection in a shorter time frame than was possible without this therapy. As a result, recreational use of sildenafil is common. However, although not a well established risk, there are case reports of stroke in men taking high dose sildenafil [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In a systematic review of published studies, sildenafil use among homosexual men was associated with sexual risk behavior, and risk of sexually transmitted diseases, including HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Vardenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     Vardenafil",
"    </a>",
"    shares a similar structure, onset and duration of action and side-effect profile with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , and is available as a 10 and 20 mg dose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/40\">",
"     40",
"    </a>",
"    ]. Although there are no direct comparison studies, vardenafil appears to be as effective as sildenafil [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. The duration of action, like sildenafil, is approximately four hours (",
"    <a class=\"graphic graphic_table graphicRef80719 \" href=\"UTD.htm?23/9/23710\">",
"     table 2A",
"    </a>",
"    ). The following observations illustrate both efficacy and potential concerns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 805 men ages 57 to 78 with erectile dysfunction of various etiologies randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      5, 10, or 20 mg or placebo as needed for six months, vardenafil was more effective than placebo for improving penetration (64 to 80 versus 50 percent, respectively) and maintenance of erections (50 to 67 versus 32 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/43\">",
"       43",
"      </a>",
"      ]. Similar results were noted in a second large, randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       Vardenafil",
"      </a>",
"      is also more effective than placebo for men with erectile dysfunction due to diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/45\">",
"       45",
"      </a>",
"      ] or nerve-sparing radical prostatectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/46\">",
"       46",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38341?source=see_link\">",
"       \"Erectile dysfunction in diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H683372924#H683372924\">",
"       \"Radical prostatectomy for localized prostate cancer\", section on 'Nerve-sparing approach'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      High-fat, but not moderate-fat meals, may lower",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      's peak serum concentration by approximately 18 percent, and delay its absorption by one hour [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A slight prolongation of the QT interval may occur, but this is not thought to be clinically important [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/48\">",
"       48",
"      </a>",
"      ]. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      should not be used in men with congenital QT prolongation or in those taking antiarrhythmics drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Side effects are similar to those seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      , and include headache, flushing, and rhinitis, in 13, 10, and 10 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/43,45\">",
"       43,45",
"      </a>",
"      ]. In one trial, side effects decreased over time [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/43\">",
"       43",
"      </a>",
"      ]. Changes in color vision (blue vision) have not been reported thus far [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/40\">",
"       40",
"      </a>",
"      ]. Issues related to sexual activity in men with coronary heart disease are similar to those with sildenafil. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"       \"Sexual activity in patients with heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    appears to be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    with no evidence of a more rapid onset of action or other clinical advantages. Like sildenafil, vardenafil is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in men taking concurrent nitrates.",
"   </p>",
"   <p>",
"    Package labeling for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    had initially listed concurrent use of alpha-blockers as a contraindication. However, the labeling has been revised to state that patients should be stable on alpha-blocker therapy prior to initiating vardenafil (which should be started at the lowest recommended dose). In patients already taking vardenafil, alpha-blocker therapy should be started at the lowest dose possible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tadalafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     Tadalafil",
"    </a>",
"    has a different chemical structure than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/50\">",
"     50",
"    </a>",
"    ]. Although there are no direct comparison studies, tadalafil also appears to be as effective as sildenafil but has a longer duration of action [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In addition, it does not cause blue vision (as described below), but otherwise shares a similar side-effect profile with the other two phosphodiesterase inhibitors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     Tadalafil",
"    </a>",
"    is approved in Europe, the United States, and many other countries. The recommended starting dose for as-needed use is 10 mg, increasing to 20 mg if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/53\">",
"     53",
"    </a>",
"    ]. Lower doses of tadalafil (2.5 mg, 5 mg) are available for once daily administration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/54\">",
"     54",
"    </a>",
"    ]; this approach appears to be as effective as taking higher doses on an as-needed basis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/55\">",
"     55",
"    </a>",
"    ]. Food does not interfere with its absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current FDA labeling includes warnings about daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    use and drug interactions (the once-daily dose should not exceed 2.5 mg in patients receiving CYP3A4 inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ). Alcohol should be avoided, and caution is advised in patients with hepatic dysfunction. Daily dose tadalafil should not be used in patients with severe renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efficacy of daily use is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an integrated analysis of randomized trials in 1112 men with erectile dysfunction receiving 2.5, 5, 10, or 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      or placebo, 75 percent of intercourse attempts were successful in the tadalafil group compared with 32 percent with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study in 348 men, 59 percent of intercourse attempts were successful at 36 hours with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      (20 mg) compared with 28 percent with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects are similar to those seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    with headache, dyspepsia, flushing, and rhinitis occurring in 8 to 14, 5 to 10, 4 to 6, and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/51,58\">",
"     51,58",
"    </a>",
"    ]. The duration of these side effects is not known. In one study, back pain occurred in 6 percent of patients taking the 20 mg dose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/53\">",
"     53",
"    </a>",
"    ]. In general, the pain occurred 12 to 24 hours after dosing, was mild, and resolved within 48 hours. Visual side effects have not been described.",
"   </p>",
"   <p>",
"    A possible association with sudden hearing loss is described above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Hearing loss'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in men taking concurrent nitrates. In spite of its longer half life, the time course of nitrate interaction with tadalafil does not appear to be prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/59\">",
"     59",
"    </a>",
"    ]. However, it has been suggested that nitrates should be avoided for at least 48 hours after the last tadalafil dose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/60\">",
"     60",
"    </a>",
"    ]. Other issues related to sexual activity in men with coronary heart disease are similar to those with sildenafil. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"     \"Sexual activity in patients with heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alpha adrenergic antagonists, which are commonly used for the treatment of benign prostatic hyperplasia, may cause symptomatic hypotension when taken in combination with PDE-5 inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     Tamsulosin",
"    </a>",
"    is the least likely to cause orthostatic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current labeling for all three PDE-5 inhibitors recommends that patients should be stable on alpha blocker therapy prior to initiating a PDE-5 inhibitor (which should then be started at the lowest recommended dose). Conversely, in patients already taking a PDE-5 inhibitor, alpha blocker therapy should be initiated at the lowest dose.",
"   </p>",
"   <p>",
"    Excessive alcohol intake (five or more drinks) in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    administration may potentiate the hypotensive effect of tadalafil [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of potent CYP3A4 inhibitors should be avoided as described above for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare case reports of nonarteritic anterior ischemic optic neuropathy have been described with the PDE-5 inhibitors, prompting the United States Food and Drug Administration to require revised labeling to reflect this potential risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Visual effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to PDE-5, an extensive family of phosphodiesterases exist, some with defined and others with not yet clarified roles in human physiology. PDE-6 is present in the retina and has a role in color vision. The PDE-5 inhibitor in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    cross-reacts with the retinal PDE-6 and accounts for the transient \"blue vision\" side effect reported in a small percentage of sildenafil-treated men.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     Tadalafil",
"    </a>",
"    does not appear to disrupt PDE-6 so blue vision has not been reported with this medication.",
"   </p>",
"   <p>",
"    Daily use of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    does not appear to be associated with retinal toxicity, as illustrated by a trial of 143 men who were randomly assigned to receive sildenafil 50 mg, tadalafil 5 mg, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/61\">",
"     61",
"    </a>",
"    ]. After six months of therapy, there were no abnormalities in visual function or electroretinograph recordings suggestive of drug toxicity in the treatment groups compared to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Reproductive effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     Tadalafil",
"    </a>",
"    does show some cross reactivity with PDE-11, an enzyme that is present in the testes and pituitary, but the physiologic significance of this enzyme is unclear. Tadalafil does not appear to disrupt any aspect of normal pituitary or testicular function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/62\">",
"     62",
"    </a>",
"    ]. This was illustrated in a study of 421 men over age 45 who were randomly assigned to receive placebo (n = 101) versus tadalafil 10 mg (n = 103), or placebo (n = 106) versus tadalafil 20 mg (n = 111) daily for six months. During this interval, when compared to placebo, six months of daily administration of tadalafil caused no change in sperm concentration, sperm count, motility or morphology and did not alter serum LH, FSH or testosterone concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Comparisons",
"    </span>",
"    &nbsp;&mdash;&nbsp;All PDE-5 inhibitors allow men to have erections after appropriate sexual stimulation but differ in the onset of action as well as duration of effectiveness.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     Tadalafil",
"    </a>",
"    differs in two ways. Its absorption is less affected by high fat meals and alcohol and it has a longer duration of action.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    has the longest safety record of the three drugs.",
"   </p>",
"   <p>",
"    With",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    men are advised that maximum effectiveness is achieved by taking the tablet on an empty stomach (high fat meals and alcohol appear to delay the absorption of both drugs) and then wait at least an hour before attempting sexual intercourse.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     Tadalafil",
"    </a>",
"    can be taken without regard to meals.",
"   </p>",
"   <p>",
"    The period of effectiveness for a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    is four hours. For men with mild to moderate ED, the efficacy of sildenafil may persist for 8 to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/63\">",
"     63",
"    </a>",
"    ]. Men with erectile dysfunction may have an erection in response to sexual stimulation for up to 36 hours after a single",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    dose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one international multi-center double-blind crossover study comparing patient preference for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    50 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    20 mg, 215 men (mostly sildenafil na&iuml;ve men) with erectile dysfunction age 65 and younger were randomized to receive each medication for four weeks with an intervening one week washout period before switching to the other medication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/64\">",
"     64",
"    </a>",
"    ]. The following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men reported a similar number of sexual intercourse episodes: 2334 with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      and 2233 with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      At the end of the study, 66.3 percent of men expressed a preference for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      and 33.7 percent for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      as a treatment for their erectile dysfunction.",
"     </li>",
"     <li>",
"      The interval between dosing and sexual intercourse differed. On average",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      -treated men had sex 2.2 hours after dosing well within the 4 hour window of opportunity stipulated on the label whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      -treated men were able to maintain efficacy but were able to delay sexual intercourse for 5.5 hours after dosing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently available PDE-5 inhibitors result in similarly high rates of successful sexual intercourse (68 to 69 percent compared to 33 to 35 percent for placebo), and similar side effect profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/65\">",
"     65",
"    </a>",
"    ]. Therefore, a Clinical Practice Guideline from The American College of Physicians recommends that the choice of PDE-5 inhibitor be based upon on the patient's preferences, including cost, ease of use, and adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Supplements containing PDE-5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA has issued a warning to consumers not to purchase or consume dietary supplements that claim to increase sexual stamina, confidence, and performance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    claim to contain prescription-strength doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Current studies suggest that one-third to one-half of supplements claiming to be &ldquo;natural&rdquo; products for sexual enhancement contain synthetic chemicals, most commonly, PDE-5 inhibitors or analogs of PDE-5 inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The concern is that patients who take nitrates for cardiovascular disease may experience a drastic lowering of blood pressure if these supplements are consumed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;All three PDE-5 inhibitors:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    work to sustain levels of cyclic GMP within the penile corpora cavernosae to allow men with erectile dysfunction to achieve erections in response to appropriate sexual stimuli.",
"   </p>",
"   <p>",
"    Duration of action separates one PDE-5 inhibitor from another.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    are effective as early as 30 minutes and up to four hours after dosing whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    is effective as early as 16 minutes after and up to 36 hours after dosing.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    must be taken on an empty stomach, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    can be taken without regard to food.",
"   </p>",
"   <p>",
"    An important factor in the success of PDE-5 inhibitor therapy is instruction and counseling on proper use and administration. Repeat challenge with proper instruction and counseling of patients labeled as PDE-5 inhibitor failures has been demonstrated to salvage approximately 25 to 30 percent of patients who were apparent initial non-responders to PDE-5 inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    result in similarly high rates of successful sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/65\">",
"     65",
"    </a>",
"    ]. Side effect profiles are similar; only rarely do men with erectile dysfunction discontinue treatment because of side effects. Current practice guidelines recommend that the choice of PDE-5 inhibitor should be based upon on the patient's preferences, including cost, ease of use, and adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Penile self-injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapenile injection therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    (prostaglandin E1, Caverject),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    , or alprostadil with papaverine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    (Tri-Mix) have all been used for purposes of inducing erection.",
"   </p>",
"   <p>",
"    The sympathetic nervous system normally maintains the penis in a flaccid or non-erect state. All of these vasoactive drugs, when injected into the corpora cavernosae, inhibit or override sympathetic inhibition to encourage relaxation of the smooth muscle trabeculae within the penile erectile bodies. The ensuing onrush of blood engorges the penile corpora cavernosae sinusoidal spaces with sufficient pressure to compress the emissary veins that normally drain blood from the penis. The combination of accelerated arterial inflow and impeded venous outflow from the corpora cavernosae creates an erection (",
"    <a class=\"graphic graphic_figure graphicRef60979 \" href=\"UTD.htm?32/32/33283\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Considerable education is required for men to become facile with this form of therapy. Under the guidance of urologists men are trained in sterile methods and the proper technique for inserting an insulin syringe with a 26 gauge needle through the shaft of the penis and injecting the vasoactive agent into one corporeal body (",
"    <a class=\"graphic graphic_figure graphicRef60326 \" href=\"UTD.htm?14/61/15312\">",
"     figure 2",
"    </a>",
"    ). The cross circulation of the penile corpora allows medication injected into one penile corporeal body to diffuse over to the contralateral side so that a full, firm erection can be expected within a few minutes after intrapenile installation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Specific drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early days of penile self-injection therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    proved to be more reliable than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    in producing an erection. Papaverine is a parenteral vasodilator with marginal efficacy in peripheral vascular disease, while phentolamine is an alpha-adrenergic blocker used for hypertensive crises in pheochromocytoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     Alprostadil",
"    </a>",
"    was originally introduced to maintain the patency of the ductus arteriosus before definitive cardiac surgery could be undertaken. When it became apparent that it was effective in a penile self-injection program, the pharmaceutical company making alprostadil was granted approval by the Food and Drug Administration in the United States to market alprostadil under the name Caverject as a treatment for erectile dysfunction. In comparison, the purveyors of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    never promoted, and indeed warned against, using their medications for penile self-injection. Nevertheless, alprostadil and papaverine remain popular as monotherapy, and all three drugs can be given together.",
"   </p>",
"   <p>",
"    The efficacy and safety of a program of at-home intrapenile",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    injections were then investigated in a six-month study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/74\">",
"     74",
"    </a>",
"    ]. Six hundred and eighty three men with vasculogenic, neurogenic, psychogenic, and mixed causes of erectile dysfunction entered the trial and 471 (69 percent) completed the trial. The reasons for drop out included penile pain, lack of efficacy, loss to follow-up, dislike of self injection, and other problems. Sexual activity, recorded as sexual intercourse or masturbation, was reported by 551 men over the six-month period. A total of 11,223 instances of sexual intercourse and 701 masturbatory episodes occurred after 13,762 intrapenile alprostadil injections. This pattern of sexual activity was deemed to be satisfactory by 87 percent of the men completing the trial and 86 percent of their partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Attrition rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the relatively high success rate, there is a very high attrition rate with self-injection, suggesting that it may not be a satisfactory long-term solution in the treatment for many men with erectile dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effect of intrapenile",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    therapy is penile pain, occurring in 50 percent. Pain was the side effect most often cited by men who discontinued therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h4\">",
"     Priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Priapism, or a prolonged erection lasting more than four to six hours, is a medical emergency often requiring immediate urologic attention to evacuate blood clogged within the corpora cavernosae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/75\">",
"     75",
"    </a>",
"    ]. Prolonged erections occur in 6 percent of men who use intrapenile",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    and about 11 percent of those who use intrapenile",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Lower doses should be used in men with neuropathic erectile dysfunction (due to spinal cord injury or multiple sclerosis), due to their risk of priapism.",
"   </p>",
"   <p>",
"    One study evaluated the effects of prolonged priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most priapism that lasted 36 hours could be treated successfully by puncture and alpha-adrenergic drugs without any fibrosis of the corpora cavernosa.",
"     </li>",
"     <li>",
"      After 48 hours, glandulocavernosal shunts were required to achieve detumescence. All the men developed fibrosis of the corpora cavernosa and all but one were unable to continue with the injections of vasoactive drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     Papaverine",
"    </a>",
"    injected into the corpora cavernosae may escape into the general circulation and can be hepatotoxic; abnormal liver function tests have been reported in men using this drug for penile self-injection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/77\">",
"     77",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    is metabolized within the corpora and does not adversely affect the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Intraurethral alprostadil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraurethral administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    (MUSE) provides a less invasive alternative to intrapenile injection. The efficacy of intraurethral alprostadil was evaluated in a double-blind, placebo-controlled trial in 1511 men with chronic erectile dysfunction from a variety of organic causes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/78\">",
"     78",
"    </a>",
"    ]. Two-third of these men responded to intraurethral alprostadil with an erection sufficient for intercourse; these men were then randomly assigned to therapy with either alprostadil or placebo. Successful intercourse on at least one occasion was much more likely with alprostadil (65 versus 19 percent with placebo). Among the men who responded to alprostadil, 7 of 10 applications were followed by successful intercourse.",
"   </p>",
"   <p>",
"    After insertion of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    into the urethra, the penis should be massaged for up to one minute to ensure equal distribution in the corpora cavernosae.",
"   </p>",
"   <p>",
"    Systemic effects were uncommon, and complications such as priapism and penile fibrosis were less common than after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    given by penile injection. The 19 percent response rate in the placebo group suggests that psychogenic factors were responsible for the sexual dysfunction, since placebo injections do not induce erections in solely organic causes of impotence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     VACUUM-ASSISTED ERECTION DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mechanical devices have been developed which utilize vacuum pressure to encourage increased arterial inflow and occlusive rings to discourage venous egress from the penile corpora cavernosae (",
"    <a class=\"graphic graphic_figure graphicRef54878 \" href=\"UTD.htm?24/2/24623\">",
"     figure 3",
"    </a>",
"    ). A certain amount of mechanical dexterity is required to use these devices effectively, but once men become comfortable with using the vacuum and restraining rings they can create an erection sufficient for vaginal penetration and sexual intercourse. They cannot, however, ejaculate externally because the occlusive rings that prevent venous drainage also compress the penile urethra sufficiently to prevent seminal fluid from reaching and traversing the urethral meatus. A number of devices are available for purchase over the counter.",
"   </p>",
"   <p>",
"    Vacuum devices successfully create erections in as many as 67 percent of patients. Satisfaction with vacuum-assisted erections has varied between 25 and 49 percent. As an example, one prospective study evaluated 18 men by questionnaire at six months: 16 (89 percent) were able to attain satisfactory erections, and the overall satisfaction rate was 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/79\">",
"     79",
"    </a>",
"    ]. Sixteen of the 18 men found the device easy to use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PENILE PROSTHESES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enthusiasm for drug and penile injection therapy has greatly reduced reliance on surgical implants of penile prostheses as treatment for men with erectile dysfunction. This form of therapy remains a viable option for those men who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and find penile injection or vacuum erection therapy distasteful. There are two general types of prostheses: malleable rods and inflatable prostheses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=see_link\">",
"     \"Surgical treatment of erectile dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects include those related to the anesthesia, local wound infections, and mechanical failure necessitating surgical removal and reimplantation of a new functioning prosthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Psychotherapy and psychoactive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychological counseling, including the use of sensate focus exercises by both partners, can be helpful when the man is suffering from performance anxiety. This is usually best accomplished by referral to a certified sexual therapy counselor.",
"   </p>",
"   <p>",
"    Erectile dysfunction is also a common symptom of depression and potency is usually restored as psychotherapy or antidepressant drugs alleviate the depression. However, many of the newest and most effective antidepressant drugs of the serotonin reuptake inhibitor class (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ) decrease both libido and erectile function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/80\">",
"     80",
"    </a>",
"    ]. On the other hand,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    can cause delayed or retarded ejaculation, a \"side effect\" that may actually be beneficial for men suffering from premature ejaculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Yohimbine",
"    </span>",
"    &nbsp;&mdash;&nbsp;By blocking presynaptic alpha-2-adrenergic receptors, yohimbine increases cholinergic and decreases adrenergic tone, changes that should theoretically be effective in men with psychogenic erectile dysfunction. Although a rich folk lore has imbued yohimbine with mystical aphrodisiacal properties, it has limited clinical effectiveness.",
"   </p>",
"   <p>",
"    Optimal results are achieved when yohimbine use is restricted to men with psychogenic erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. As an example, two double-blind, placebo-controlled studies evaluated 101 men with psychogenic erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/81\">",
"     81",
"    </a>",
"    ]. Erectile function and sexual intercourse resumed in 37 percent of men treated with yohimbine (5.4 mg TID) within three days to three weeks of starting therapy; only 15 percent of placebo-treated men had a comparable response.",
"   </p>",
"   <p>",
"    In contrast, a randomized, double-blind study of 29 men with erectile dysfunction of unclear etiology but no known endocrine or psychologic cause showed no difference between yohimbine and placebo; in both groups almost half improved [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/83\">",
"     83",
"    </a>",
"    ]. A virtual lack of response was also noted in 20 men with erectile dysfunction due to arterial insufficiency and cavernous venous leakage who were treated with either a combination of yohimbine and isoxsuprine or pentoxifylline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis reviewed this confused set of data on the efficacy of yohimbine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/85\">",
"     85",
"    </a>",
"    ]. Seven randomized controlled trials of reasonable quality were found and evaluated; the investigators concluded that there was enough evidence to recommend a trial of yohimbine as initial therapy (odds ratio: 3.9).",
"   </p>",
"   <p>",
"    In practice, the prompt onset of action in \"responders\" has encouraged clinicians to consider a trial of yohimbine in men with apparent psychogenic erectile dysfunction. Treatment is continued only in those who respond and also tolerate the drug's side effects, which include dizziness, flushing, nausea, and headache.",
"   </p>",
"   <p>",
"    Yohimbine should be used with caution in patients with heart disease because of its cardiovascular side effects, including tachycardia and the potential for hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"     \"Sexual activity in patients with heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Androgen replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If sexual dysfunction is associated with testosterone deficiency, testosterone therapy to restore normal range testosterone levels can be achieved with either transdermal testosterone gels, patches or testosterone injections. Each of these preparations has its own advantages and disadvantages. The different preparations and goals of therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Role of vascular surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For an erection to occur blood must flow through a network of arteries all branching from the iliac artery and then on to smaller tributaries ending at the helicine arteries that feed the corpora cavernosae. During moments of sexual excitation blood flows into the corpora cavernosae under such high pressure that if first causes penile swelling (tumescence) and then compresses the emissary veins that normally drain blood form the corpora cavernosae creating a rigid erection. Any condition that compromises arterial flow to the genital area can cause impotence by a \"failure to fill\" whereas premature egress of venous blood out of the emissary veins would set the stage for a \"failure to store\" form of erectile dysfunction.",
"   </p>",
"   <p>",
"    Surgical techniques have been devised to alleviate arterial occlusions and correct \"failure to fill\" and also shore up sagging veins in men when \"failure to store\" seemed to be the root cause of their sexual dysfunction. Although these surgical procedures had enjoyed some popularity in the past, long-term sexual outcomes have been quite poor, with the exception of young patients with traumatic arterial lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Melanocortin receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanocortin receptor agonists, which act on the central nervous system rather than the vascular system, are being developed as a possible new therapy for erectile dysfunction. PT-141, an intranasal preparation, appears to be effective as monotherapy or in combination with PDE-5 inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. However, significant side effects, including flushing and nausea, may limit its clinical utility. This agent is neither approved for use nor commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     PREMATURE EJACULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature ejaculation (or rapid ejaculation) is defined as an inability to control ejaculation so that both partners enjoy sexual intercourse. Approximately 20 percent of men complain of premature ejaculation, most of whom have no underlying physical abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/90\">",
"     90",
"    </a>",
"    ]. Nonpharmacologic therapy such as the \"pause and squeeze\" technique has achieved variable success [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/90\">",
"     90",
"    </a>",
"    ], but drug therapy has proved quite useful.",
"   </p>",
"   <p>",
"    Several psychoactive drugs can cause delayed or retarded ejaculation, and some have been evaluated for the treatment of premature ejaculation. In one double-blind study, 37 potent men ages 19 to 70 years who complained of premature ejaculation were randomly assigned to receive the selective serotonin reuptake inhibitor (SSRI)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/91\">",
"     91",
"    </a>",
"    ]. The mean ejaculatory latency time before treatment in both groups was 0.3 minutes and the mean interval after four weeks of treatment was 0.5 minutes in the placebo group and 3.2 minutes in the sertraline group, a significant difference. In a subsequent open-label phase of the study, 20 of 29 men (67 percent) were able to discontinue the drug after a mean of seven months and maintain a mean ejaculatory latency time greater than four minutes. Other SSRIs also appear to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intermittent use of SSRIs may be as effective as continuous use. This issue was examined in a study of 26 men with premature ejaculation who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (20 mg) or placebo as needed three to four hours before planned intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/94\">",
"     94",
"    </a>",
"    ]. The mean ejaculatory latency time was significantly greater in the paroxetine group compared with placebo after four weeks (3.2 versus 0.45 minutes). In a second phase of the study involving 42 men, treatment with paroxetine daily for three weeks prior to using it on an as needed basis improved ejaculatory control compared to men who only used the drug only as needed.",
"   </p>",
"   <p>",
"    An additional SSRI, dapoxetine, also appears to be effective, based upon two randomized trials of nearly 2000 men with premature ejaculation who were randomly assigned to receive placebo or dapoxetine (30 mg or 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/95\">",
"     95",
"    </a>",
"    ]. Unlike other SSRIs, which are taken daily, dapoxetine is taken on-demand one to three hours before intercourse. The mean ejaculatory latency time before treatment in all groups was approximately 0.9 minutes, while the mean intervals in the placebo and dapoxetine groups (30 and 60 mg) on treatment were 1.8, 2.8, and 3.3 minutes, respectively. The most common side effect with dapoxetine was nausea (8 and 20 percent with 30 and 60 mg, respectively). Dapoxetine is not commercially available in all countries.",
"   </p>",
"   <p>",
"    The tricyclic antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    is useful and possibly more effective than SSRIs in prolonging the interval from intromission to ejaculation. In one study of 36 men with premature ejaculation, four weeks of treatment with either placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , or clomipramine resulted in increased ejaculation time from 46 seconds (placebo) to 2.27 minutes (fluoxetine), 4.27 minutes (sertraline), and 5.75 minutes (clomipramine) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/96\">",
"     96",
"    </a>",
"    ]. However, significantly more side effects, most notably dry mouth, occurred in patients treated with clomipramine.",
"   </p>",
"   <p>",
"    One small trial suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    may be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    and SSRIs for premature ejaculation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/36/30282/abstract/97\">",
"     97",
"    </a>",
"    ], but this has not been confirmed in larger studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"       \"Patient information: Sex problems in men (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"       \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Erectile dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with erectile dysfunction, we recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For first-line therapy, we recommend the phosphodiesterase inhibitors (PDE-5 inhibitors) because of their efficacy, ease of use, and favorable side effect profile (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      appear to be equally effective, but tadalafil has a longer duration of action. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current practice guidelines suggest that the choice of PDE-5 inhibitor should be based upon on the patient's preferences, including cost, ease of use, and adverse effects. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Choice of drug'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phosphodiesterase inhibitors are",
"      <strong>",
"       contraindicated",
"      </strong>",
"      in men taking concurrent nitrates.",
"     </li>",
"     <li>",
"      We suggest that alpha adrenergic antagonists not be used concurrently with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      (due to potential hypotension with combination therapy), with the possible exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"       tamsulosin",
"      </a>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      which appears to be safe when taken with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the clinician and patient choose to use PDE-5 inhibitors with alpha-blockers, we suggest that in patients on stable alpha-blocker therapy, PDE-5 inhibitors should be initiated at the lowest possible dose. In patients already taking an optimized dose of PDE-5 inhibitor, alpha-blocker therapy should be initiated at the lowest possible dose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      be taken on an empty stomach, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      may be taken without regard to food.",
"     </li>",
"     <li>",
"      There are several second line therapies that have been shown to be effective: penile self-injectable drugs, intraurethral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"       alprostadil",
"      </a>",
"      , and vacuum devices. We suggest choosing among these options based upon patient preference (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Penile self-injection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Vacuum-assisted erection devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that surgical implantation of a penile prosthesis be reserved for men who cannot use or who have not responded to first- and second-line therapies (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Penile prostheses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend androgen replacement therapy only in men with documented hypogonadism (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Androgen replacement therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"       \"Testosterone treatment of male hypogonadism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"       \"Overview of testosterone deficiency in elderly men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Premature ejaculation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest selective serotonin reuptake inhibitors (SSRIs) as first-line therapy, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      as second-line therapy for men with premature ejaculation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These recommendations are consistent with AUA guidelines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265972\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to acknowledge the late Dr. Richard F Spark, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/1\">",
"      Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004; 328:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/2\">",
"      Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004; 172:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/3\">",
"      Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005; 174:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/4\">",
"      Qaseem A, Snow V, Denberg TD, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2009; 151:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/5\">",
"      Guay AT, Spark RF, Bansal S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. Endocr Pract 2003; 9:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/6\">",
"      Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/7\">",
"      Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006; 18:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/8\">",
"      Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med 2010; 7:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/9\">",
"      Lamina S, Okoye CG, Dagogo TT. Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/10\">",
"      Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011; 171:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/11\">",
"      Dadkhah F, Safarinejad MR, Asgari MA, et al. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res 2010; 22:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/12\">",
"      Herrmann HC, Levine LA, Macaluso J Jr, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 2006; 3:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/13\">",
"      Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/14\">",
"      Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/15\">",
"      Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/16\">",
"      Schover LR, Fouladi RT, Warneke CL, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002; 95:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/17\">",
"      Zippe CD, Kedia AW, Kedia K, et al. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998; 52:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/18\">",
"      Dinsmore WW, Hodges M, Hargreaves C, et al. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/19\">",
"      Fink HA, Mac Donald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/20\">",
"      Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/21\">",
"      Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86:57F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/22\">",
"      Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/23\">",
"      Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/24\">",
"      Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/25\">",
"      Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999; 99:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/26\">",
"      Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/27\">",
"      Stauffer JC, Ruiz V, Morard JD. Subaortic obstruction after sildenafil in a patient with hypertrophic cardiomyopathy. N Engl J Med 1999; 341:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/28\">",
"      Pomara G, Morelli G, Pomara S, et al. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. J Androl 2004; 25:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/29\">",
"      The Medical Letter December 22. 2003; 45:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/30\">",
"      Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/31\">",
"      Vobig MA, Klotz T, Staak M, et al. Retinal side-effects of sildenafil. Lancet 1999; 353:375.",
"     </a>",
"    </li>",
"    <li>",
"     The Medical Letter 2005; 47:49.",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/consumerinfo/viagra/vIAGRA.htm (accessed online 7/11/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/34\">",
"      Zrenner E. No cause for alarm over retinal side-effects of sildenafil. Lancet 1999; 353:340.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/bbs/topics/NEWS/2007/NEW01730.html (accessed on 10/22/07).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/36\">",
"      Aversa A, Mazzilli F, Rossi T, et al. Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod 2000; 15:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/37\">",
"      Kim KK, Kim DG, Ku YH, et al. Bilateral cerebral hemispheric infarction associated with sildenafil citrate (Viagra) use. Eur J Neurol 2008; 15:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/38\">",
"      Alpsan MH, Bebek N, Ciftci FD, et al. Intracerebral hemorrhage associated with sildenafil use: a case report. J Neurol 2008; 255:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/39\">",
"      Swearingen SG, Klausner JD. Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection. Am J Med 2005; 118:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/40\">",
"      Vardenafil (levitra) for erectile dysfunction. Med Lett Drugs Ther 2003; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/41\">",
"      Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/42\">",
"      Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/43\">",
"      Hellstrom WJ, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/44\">",
"      Valiquette L, Young JM, Moncada I, et al. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005; 80:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/45\">",
"      Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/46\">",
"      Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/47\">",
"      Rajagopalan P, Mazzu A, Xia C, et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/48\">",
"      Borer J, Armstrong P, Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation 2003; 107:e9052.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/cder/warn/2005/Levitra.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/50\">",
"      Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/51\">",
"      Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/52\">",
"      Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 Suppl 1:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/53\">",
"      \"The Pink Sheet\". 2003; 65:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/54\">",
"      Tadalafil (Cialis) once a day for erectile dysfunction. Med Lett Drugs Ther 2008; 50:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/55\">",
"      Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/56\">",
"      Bella AJ, Brock GB. Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep 2003; 4:472.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/CDER/DRUG/infopage/cialis/cialisQ&amp;A.htm (accessed on 5/29/08).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/58\">",
"      Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/59\">",
"      Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42:1855.",
"     </a>",
"    </li>",
"    <li>",
"     Pharmaceutical Approvals Monthly April 2004; 9:21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/61\">",
"      Cordell WH, Maturi RK, Costigan TM, et al. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol 2009; 127:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/62\">",
"      Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003; 170:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/63\">",
"      McCullough AR, Steidle CP, Klee B, Tseng LJ. Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. Urology 2008; 71:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/64\">",
"      Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/65\">",
"      Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009; 151:650.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/bbs/topics/ANSWERS/2003/ANS01235.html (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/67\">",
"      Mitka M. FDA issues warning on \"all-natural\" herbal product found to contain viagra. JAMA 2003; 289:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/68\">",
"      Venhuis BJ, Blok-Tip L, de Kaste D. Designer drugs in herbal aphrodisiacs. Forensic Sci Int 2008; 177:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/69\">",
"      Savaliya AA, Shah RP, Prasad B, Singh S. Screening of Indian aphrodisiac ayurvedic/herbal healthcare products for adulteration with sildenafil, tadalafil and/or vardenafil using LC/PDA and extracted ion LC-MS/TOF. J Pharm Biomed Anal 2010; 52:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/70\">",
"      Hatzimouratidis K, Moysidis K, Bekos A, et al. Treatment strategy for \"non-responders\" to tadalafil and vardenafil: a real-life study. Eur Urol 2006; 50:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/71\">",
"      Gruenwald I, Shenfeld O, Chen J, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006; 50:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/72\">",
"      Govier FE, McClure RD, Weissman RM, et al. Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993; 150:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/73\">",
"      Shenfeld O, Hanani J, Shalhav A, et al. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol 1995; 154:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/74\">",
"      Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996; 334:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/75\">",
"      Carson, CC 3rd, Mino, RD. Priapism associated with trazodone therapy. J Urol 1988; 139:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/76\">",
"      Kulmala RV, Tamella TL. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs. Int J Impot Res 1995; 7:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/77\">",
"      Levine SB, Althof SE, Turner LA, et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/78\">",
"      Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/79\">",
"      Tay KP, Lim PH. A prospective trial with vacuum-assisted erection devices. Ann Acad Med Singapore 1995; 24:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/80\">",
"      Herman JB, Brotman AW, Pollack MH, et al. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/81\">",
"      Riley, AJ, Goodman, RE, Kellett, JM, et al. Double blind trial of yohimbine hydrochloride in erection inadequacy. J Sexual Marital Therapy 1989; 4:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/82\">",
"      Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology 1994; 44:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/83\">",
"      Kunelius P, H&auml;kkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology 1997; 49:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/84\">",
"      Knoll LD, Benson RC Jr, Bilhartz DL, et al. A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol 1996; 155:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/85\">",
"      Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/86\">",
"      Wespes E, Wildschutz T, Roumeguere T, Schulman CC. The place of surgery for vascular impotence in the third millennium. J Urol 2003; 170:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/87\">",
"      Siroky MB, Azadzoi KM. Vasculogenic erectile dysfunction: newer therapeutic strategies. J Urol 2003; 170:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/88\">",
"      Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/89\">",
"      Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology 2005; 65:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/90\">",
"      Gregoire A. ABC of sexual health: assessing and managing male sexual problems. BMJ 1999; 318:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/91\">",
"      McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998; 159:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/92\">",
"      Kara H, Aydin S, Y&uuml;cel M, et al. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 1996; 156:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/93\">",
"      Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994; 151:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/94\">",
"      McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol 1999; 161:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/95\">",
"      Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/96\">",
"      Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998; 159:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/36/30282/abstract/97\">",
"      Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001; 13:41.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7469 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30282=[""].join("\n");
var outline_f29_36_30282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72305449\">",
"      CARDIOVASCULAR RISK FACTOR REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72305547\">",
"      Phosphodiesterase 5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Visual effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recreational use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Vardenafil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tadalafil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Reproductive effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Comparisons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Supplements containing PDE-5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Penile self-injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Specific drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Attrition rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Intraurethral alprostadil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      VACUUM-ASSISTED ERECTION DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PENILE PROSTHESES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Psychotherapy and psychoactive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Yohimbine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Androgen replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Role of vascular surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Melanocortin receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      PREMATURE EJACULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Premature ejaculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265972\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7469|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/32/33283\" title=\"figure 1\">",
"      Penile blood flow in erection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15312\" title=\"figure 2\">",
"      Method of penile self injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/2/24623\" title=\"figure 3\">",
"      Vacuum constrictor device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/45/11995\" title=\"table 1\">",
"      Causes male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/9/23710\" title=\"table 2A\">",
"      Oral Rx sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/33/29212\" title=\"table 2B\">",
"      Nonoral Rx sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38341?source=related_link\">",
"      Erectile dysfunction in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=related_link\">",
"      Surgical treatment of erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_36_30283="Cancer tests for back pain";
var content_f29_36_30283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic tests for cancer as cause of low back pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Erythrocyte sedimentation rate (ESR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;20 mm/hr",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.78",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;50 mm/hr",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.56",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &ge;100 mm/hr",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.22",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.996",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia (hematicrit &lt;40 percent for men or &lt;38 percent for women)",
"       </td>",
"       <td>",
"        0.54",
"       </td>",
"       <td>",
"        0.86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematocrit &lt;30",
"       </td>",
"       <td>",
"        0.09",
"       </td>",
"       <td>",
"        0.994",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        WBC &ge;12,000",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.94",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Deyo, RA, Diehl, AK. Cancer as a cause of back pain: frequency, clinical presentation, and diagnostic strategies. J Gen Int Med 1988; 3:230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30283=[""].join("\n");
var outline_f29_36_30283=null;
var title_f29_36_30284="Guidelines for safe prehospital transportation";
var content_f29_36_30284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for safe prehospital transportation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Restraint options",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injured, but not ill",
"       </td>",
"       <td>",
"        <p>",
"         Transport in the front seat of the ambulance with the air bags off",
"        </p>",
"        <p>",
"         Transport in a forward or rear-facing EMS provider's seat",
"        </p>",
"        <p>",
"         Consider delay of transport and continue on scene care until an alternate vehicle is available",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ill or injured, but not requiring continuous/intensive monitoring or interventions",
"       </td>",
"       <td>",
"        <p>",
"         Transport in the EMS provider's seat in a size-appropriate child restraint system or an integrated seat in the EMS provider's seat that is certified by the manufacturer to meet the injury criteria of Federal Motor Vehicle Safety Standards",
"        </p>",
"        <p>",
"         Transport on a cot using three horizontal restraints across the child's torso (chest/waist/knees) and one vertical restraint across each of the child's shoulders",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ill or injured, and requiring continuous/intensive monitoring or interventions",
"       </td>",
"       <td>",
"        <p>",
"         Transport the child in a size-appropriate child restraint system that complies with the injury criteria of Federal Motor Vehicle Safety Standards secured appropriately on a cot. If this is not feasible, the following alternatives are recommended:",
"        </p>",
"        <p>",
"         Transport on a cot, head first, using three horizontal restraints across the child's torso (chest/waist/knees) and one vertical restraint across each of the child's shoulders. If restraints must be removed, they should be re-secured as quickly as possible; consider stopping the ambulance if interventions require restraint removal.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Condition requires spinal immobilization or lying flat",
"       </td>",
"       <td>",
"        <p>",
"         Transport with a size-appropriate spineboard and secure it to the cot, head first, with a tether at the foot to prevent forward movement AND three horizontal restraints across the child's torso (chest/waist/knees) and one vertical restraint across each of the child's shoulders. If this is not feasible, the following alternative is recommended:",
"        </p>",
"        <p>",
"         Transport with a standard spineboard with padding added to make the device fit the child; secure as noted above.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple transport (newborn with mother or multiple children)",
"       </td>",
"       <td>",
"        <p>",
"         Transport each as a single patient. If this is not feasible, the following alternative is recommended:",
"        </p>",
"        <p>",
"         Use space available in a non-emergency mode, driving below the maximum legal speed limit.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     National Highway Traffic Safety Administration (NHTSA). Recommendations for the Safe Transportation of Children in Emergency Ground Ambulances. Public meeting. August 5, 2010. file://www.nhtsa.gov/staticfiles/nti/ems/pdf/EMSconference05aug2010.pdf (Accessed on September 21, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30284=[""].join("\n");
var outline_f29_36_30284=null;
var title_f29_36_30285="Asperger disorder scales";
var content_f29_36_30285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rating instruments for Asperger disorder in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Scale",
"        <br/>",
"        (age group)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"        <br/>",
"        (time to complete)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reported sensitivity and specificity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purpose",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Asperger Syndrome Diagnostic Scale*",
"        </p>",
"        <p>",
"         (5 to 18 years)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         50-item questionnaire completed by parent, teacher, or clinician",
"        </p>",
"        <p>",
"         (10 to 15 minutes)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Sensitivity:",
"         </strong>",
"        </p>",
"        <p>",
"         79 percent (Asperger disorder versus non-Asperger disorder)",
"        </p>",
"        <p>",
"         84 percent (Asperger disorder versus autism)",
"        </p>",
"        <p>",
"         <strong>",
"          Specificity:",
"         </strong>",
"        </p>",
"        <p>",
"         98 percent (Asperger disorder versus non-Asperger disorder)",
"        </p>",
"        <p>",
"         93 percent (Asperger disorder versus autism)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         - Diagnostic aid",
"        </p>",
"        <p>",
"         - Monitor behavior",
"        </p>",
"        <p>",
"         - Generate IEP goals",
"        </p>",
"        <p>",
"         - Research",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Australian Scale for Asperger Syndrome",
"        </p>",
"        <p>",
"         (primary school)",
"        </p>",
"       </td>",
"       <td>",
"        24 questions rated on scale of 0 to 6",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Sensitivity:",
"         </strong>",
"         NR",
"        </p>",
"        <p>",
"         <strong>",
"          Specificity:",
"         </strong>",
"         NR",
"        </p>",
"       </td>",
"       <td>",
"        - Screener",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Autism Spectrum Screening Questionnaire",
"        </p>",
"        <p>",
"         (6 to 17 years)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         27-item questionnaire completed by parent or teacher",
"        </p>",
"        <p>",
"         (10 minutes)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Sensitivity:",
"         </strong>",
"        </p>",
"        <p>",
"         62 to 82 percent (parent);",
"        </p>",
"        <p>",
"         65 to 70 percent (teacher)",
"        </p>",
"        <p>",
"         <strong>",
"          Specificity:",
"         </strong>",
"        </p>",
"        <p>",
"         90 percent (parent);",
"        </p>",
"        <p>",
"         91 percent (teacher)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         - Screener",
"        </p>",
"        <p>",
"         - Research",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Childhood Autism Syndrome Test* (formerly Childhood Asperger Syndrome Test)",
"        </p>",
"        <p>",
"         (4 to 11 years)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         37-item questionnaire completed by parent",
"        </p>",
"        <p>",
"         (10 minutes)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Sensitivity:",
"         </strong>",
"         88 to 100 percent",
"        </p>",
"        <p>",
"         <strong>",
"          Specificity:",
"         </strong>",
"         97 to 98 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         - Screener",
"        </p>",
"        <p>",
"         - Research",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Gilliam Asperger's Disorder Scale*",
"        </p>",
"        <p>",
"         (3 to 22 years)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         32-item questionnaire completed by parent, teacher, or clinician",
"        </p>",
"        <p>",
"         (10 minutes)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Sensitivity:",
"         </strong>",
"         84 percent",
"        </p>",
"        <p>",
"         <strong>",
"          Specificity:",
"         </strong>",
"         84 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         - Diagnostic aid",
"        </p>",
"        <p>",
"         - Assess unique behavior",
"        </p>",
"        <p>",
"         - Monitor behavior",
"        </p>",
"        <p>",
"         - Generate IEP goals",
"        </p>",
"        <p>",
"         - Research",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Krug Asperger's Disorder Index",
"        </p>",
"        <p>",
"         (6 to 21 years)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         32-item questionnaire completed by parent or clinician",
"        </p>",
"        <p>",
"         (15 to 20 minutes)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Sensitivity:",
"         </strong>",
"         78 percent",
"        </p>",
"        <p>",
"         <strong>",
"          Specificity:",
"         </strong>",
"         94 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         - Screener",
"        </p>",
"        <p>",
"         - Generate IEP goals",
"        </p>",
"        <p>",
"         - Research",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IEP: individualized educational program; NR: not reported.",
"     <br/>",
"     * Includes items from the DSM-IV and ICD-10 criteria.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Campbell JM. Diagnostic assessment of Asperger's disorder: a review of five third-party rating scales. J Autism Dev Disord 2005; 35:25.",
"      </li>",
"      <li>",
"       Johnson CP, Myers SM. American Academy of Pediatrics Council on Children with Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183.",
"      </li>",
"      <li>",
"       Falkmer T, Anderson K, Falkmer M, Horlin C. Diagnostic procedures in autism spectrum disorders: a systematic literature review. Eur Child Adolesc Psychiatry 2013; Epub ahead of print.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30285=[""].join("\n");
var outline_f29_36_30285=null;
var title_f29_36_30286="Proximal tubule transport I";
var content_f29_36_30286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Model for proximal tubule transport",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of active Na+ and H2O reabsorption in the proximal tubule. Na+ enters the cell passively (dashed arrows) via carrier proteins in the luminal membrane; it is then actively transported into the intercellular space (dark solid arrow) by the Na+-K+-ATPase pump in the basolateral membrane. Water follows the movement of Na+ down the osmotic gradient created by solute transport out of the lumen. Some of this may occur through the tight junction as well as across the cell membranes. The Na+ and H2O that enter the intercellular space can either move into the peritubular capillary and be returned to the systemic circulation or leak back into the lumen across the tight junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30286=[""].join("\n");
var outline_f29_36_30286=null;
var title_f29_36_30287="Post infarct ischemia outcome";
var content_f29_36_30287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postinfarction angina with hemodynamic abnormalities predicts mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 511px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 40,848 patients with an acute myocardial infarction entered into GUSTO-I, 20 percent had recurrent ischemia after thrombolytic therapy. The 30-day and&nbsp;one year survivals were significantly lower among patients with recurrent ischemia associated with hemodynamic abnormalities (eg, hypotension) compared to patients without recurrent ischemia or those with recurrent ischemia without hemodynamic abnormalities (p &lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Betriu A, Califf RM, Bosch X, et al, for the GUSTO-I Investigators. J Am Coll Cardiol 1998; 31:94.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_36_30287=[""].join("\n");
var outline_f29_36_30287=null;
